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GENERAL INTRODUCTION
Delirium – an acute neuropsychiatric syndrome characterized by ﬂuctuating disturbances in 
attention, awareness and cognition – is a common and severe disorder in older hospitalized 
patients [1]. This syndrome affects approximately 20 to 30% of all older patients admitted 
to acute hospital wards [2] and can affect even a higher proportion of patients in the post-
operative and intensive care settings [3]. Delirium is associated with poor clinical outcomes, 
including prolonged hospital stay, loss of independence, cognitive decline and mortality 
[4, 5]. Approximately 20 to 25% of the patients who experience delirium dies within 6 to 
12 months [4], but higher mortality rates can be expected based on care setting, patient 
characteristics [6] and duration of delirium [7-10]. In older patients admitted to a general 
medicine ward, the 3-month mortality risk can increase by 11% for every additional 48 
hours that delirium persists [7]. Despite the high frequency and the clinical impact, many 
important aspects of this syndrome still need to be clariﬁed. The pathophysiological 
pathways leading to delirium are poorly understood; early recognition and prediction of 
delirium are difﬁcult and not supported by biomarkers, and an evidence–based effective 
drug to treat or prevent delirium is still not available.
Delirium is not a novel phenomenon; it has been recognized since the ancient time (4th 
century BC). Nevertheless, diagnostic criteria for delirium have only been available since 
the publication of the third edition of the Diagnostic and Statistical Manual of Mental 
Disorders in 1980 [11]. Until then, different terms were used to describe delirium, which 
complicated the detection of delirium and interpretation of research ﬁndings. The publica-
tion of the ﬁrst diagnostic criteria and soon afterwards also the introduction of screening 
tools, strongly facilitated research in delirium [11].
Up-to-date, the high need to improve the prediction, detection and treatment of delirium, 
in order to reduce morbidity and mortality, is increasingly being recognized and the num-
ber of publications mentioning delirium is rising (ﬁgure 1). Conversely, the underlying 
pathophysiology remains largely understudied (ﬁgure 1). Adequate knowledge of the 
pathophysiology is required to ﬁnd markers for early recognition and to improve delirium 
prediction, prevention and treatment.
Several mechanisms have been proposed to be involved in the pathophysiology of delirium 
and include, among others, inﬂammation, disturbances in neurotransmission, oxidative 
stress, loss of brain reserve, dysregulation of the hypothalamic-pituitary-adrenal axis, re-
duced cerebral blood ﬂow and dysregulation of the sleep-wake cycle [12]. Considering that 
different combinations of predisposing and precipitating factors can result into delirium, 
it seems most reasonable that the pathophysiology of delirium is multifactorial due to a 
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complex interplay among several biochemical pathways. However, the extent in which 
the proposed mechanisms contribute to delirium is unclear and additionally, increasing 
evidence suggests that delirium might have different pathophysiological mechanisms 
depending on the precipitating factor and the health status of the patient.
Also several drugs and drug classes may play a role in the pathogenesis of delirium. Many 
drugs commonly used by older persons interfere with one or more of the hypothesized 
mechanisms underlying delirium and therefore, it is likely that some drugs may increase 
the risk of delirium, while others may reduce or prevent the development of delirium. Drug 
use is modiﬁable and therefore, it is important to know which drugs should be considered 
as a risk factor for delirium and which ones as potential protective drugs. Nevertheless, 
there is considerable uncertainty about the risk of delirium associated with several drugs 
commonly used by older persons [13, 14].
OUTLINE OF THIS THESIS
The aims of this thesis are to investigate novel biomarkers of delirium and the potential 
role of pharmacological agents in determining delirium. The ﬁndings can contribute to a 
better understanding of delirium and may help to ﬁnd markers for early recognition and to 
improve delirium prediction, prevention and treatment.
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Figure 1. Number of PubMed publications per time-interval of 2 years for ‘delirium’ and ‘delirium patho-
physiology’ during the period 1990-2015. Search strategies can be found in supplementary ﬁle 1.
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The ﬁndings described in this thesis are based on two studies. The ﬁrst study is the Delirium 
In The Old (DITO) study, a cross-sectional study designed to investigate several advanced 
biochemical blood markers in patients with and without delirium. This study included 86 
patients aged 65 years and older who were acutely admitted to the wards of Internal 
Medicine and Geriatrics of the Erasmus Medical Center and the ward of Geriatrics of the 
Harbor Hospital, Rotterdam, the Netherlands.
The second study is a chart-review study including 905 patients aged 65 years and older 
who were acutely admitted to the ward of Geriatrics of the Erasmus Medical Center. This 
study was performed to investigate the possible association between the use of anticho-
linergic drugs and delirium. Additionally, within the framework of this study, we have 
investigated a relatively novel and easily measurable inﬂammatory marker in patients with 
and without delirium.
The ﬁrst part of this thesis, Chapter 2, focuses on several mechanisms that might play 
a role in the pathophysiology of delirium. Chapter 2.1 reports on the association of 
neopterin, interleukin-6 and insulin-like growth factor-1, which are markers of the im-
mune system, oxidative stress and brain reserve, with delirium. Chapter 2.2 focuses on 
disturbances in serotonergic and dopaminergic neurotransmission as well as oxidative 
stress in delirium. For this purpose, levels of amino acids, amino acid ratios and dopamine’s 
metabolite homovanillic acid (HVA) were investigated. In Chapter 2.3, the association 
of the neutrophil-lymphocyte ratio and other, more conventional, inﬂammatory markers 
(i.e. white blood cells, neutrophils, lymphocytes and C-reactive protein) with delirium is 
presented. Chapter 2.4 describes differences in biochemical markers (neopterin, amino 
acids, amino acid ratios and HVA) between acutely ill medical and elective cardiosurgical 
patients with delirium.
The second part of this thesis, Chapter 3, focuses on the role of pharmacological agents 
in delirium. In Chapter 3.1, the potential inﬂuence of acetylsalicylic acid on neopterin and 
tryptophan levels in patients with delirium is described. Chapter 3.2 describes differences 
in the association between anticholinergic drug use, measured with three anticholinergic 
drug scales, and delirium.
In Chapter 4, the ﬁndings described in this thesis are discussed and directions for future 
research are presented. Finally, an English and Dutch summary of this thesis are provided 
in Chapter 5.
Chapter 1
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SUPPLEMENTARY MATERIAL
File 1. Search strategies in PubMed
Search strategy for ‘Delirium’:
Query:
“Delirium”[mh] OR Delirium*[tiab]
Search strategy for ‘Delirium and pathophysiology’:
Query:
(“Delirium”[mh] OR Delirium*[tiab])
AND
(“Pathology”[mh] OR Patholog*[tiab] OR Pathophysiol*[tiab] OR Neuropathol*[tiab] OR 
Pathogenes*[tiab] OR Causal*[tiab] OR Etiology[sh] OR Etiolog*[tiab] OR “Biomarkers”[mh] 
OR biomarker*[tiab])
AND
(“Blood”[mh] OR Blood[tiab] OR “Plasma”[mh] OR Plasma[tiab] OR “Serum”[mh] OR 
Serum[tiab] OR “Cerebrospinal ﬂuid”[mh] OR Cerebrospinal ﬂuid*[tiab] OR Cerebro spinal 
ﬂuid*[tiab] OR “Biomarkers”[mh] OR Biomarker*[tiab] OR Biological marker*[tiab] OR 
Biologic marker*[tiab] OR Laboratory marker*[tiab] OR Biochemical marker*[tiab] OR Im-
munologic marker*[tiab] OR Immune marker*[tiab] OR “Urine”[mh] OR Urine*[tiab] OR 
Urine[sh])
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Chapter 2.1
Neopterin: a potential biomarker for delirium 
in elderly patients
Angelique Egberts, Eline H.A. Wijnbeld, Durk Fekkes, Milly A. van der Ploeg, 
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ABSTRACT
Background/Aim
The diagnosis of delirium is not supported by speciﬁc biomarkers. In a previous study, high 
neopterin levels were found in patients with a postoperative delirium. In the present study, 
we investigated levels of neopterin, interleukin-6 (IL-6) and insulin-like growth factor-1 
(IGF-1) in acutely ill admitted elderly patients with and without a delirium.
Methods
Plasma/serum levels of neopterin, IL-6 and IGF-1 were determined in patients aged t 65 
years admitted to the wards of Internal Medicine and Geriatrics. Differences in biomarker 
levels between patients with and without a delirium were investigated by the analysis of 
variance in models adjusted for age, sex, comorbidities and eGFR (when appropriate).
Results
Eighty-six patients were included; 23 of them with a delirium. In adjusted models, higher 
mean levels of neopterin (70.5 vs. 45.9 nmol/l, p = 0.009) and IL-6 (43.1 vs. 18.5 pg/ml, 
p = 0.034) and lower mean levels of IGF-1 (6.3 vs. 9.3 nmol/l, p = 0.007) were found in 
patients with a delirium compared to those without.
Conclusion
The ﬁndings of this study suggest that neopterin might be a potential biomarker for de-
lirium which, through oxidative stress and activation of the immune system, may play a role 
in the pathophysiology of delirium.
23
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INTRODUCTION
Delirium is an acute neuropsychiatric syndrome [1] common in the elderly and associated 
with increased morbidity and mortality, prolonged hospital stay, loss of independence and 
increased risk of dementia [2, 3]. Early recognition of a delirium might be difﬁcult and is 
not supported by biomarkers [4].
The pathophysiology of delirium is poorly understood, but it is widely accepted that 
it is multifactorial due to a complex interaction between several underlying mechanisms 
[5]. Activation of the immune system, oxidative stress, loss of neuroprotection and distur-
bances in cerebral neurotransmitter systems may all contribute to a delirium [6-9]. During 
immune activation, monocytes and macrophages are stimulated to produce neopterin in 
response to the pro-inﬂammatory cytokine interferon-gamma [10, 11]. Increased neopterin 
production has been associated with neurodegenerative disorders like Alzheimer’s disease 
[12] and Huntington’s disease [13], but also delirium after cardiac surgery [6]. To the best 
of our knowledge, the potential role of neopterin in delirium has never been investigated 
in elderly patients admitted due to acute pathology.
Immune activation is also reﬂected by the levels of the pro-inﬂammatory cytokine inter-
leukin-6 (IL-6). Increased levels have been associated with postoperative confusion [14], 
postoperative delirium [15, 16] and delirium in acutely ill elderly patients [17]. For the latter 
category, data are limited and inconsistent [8, 17].
Moreover, it has been suggested that an underlying vulnerability of the brain may predis-
pose patients to the development of a delirium [2, 18]. In several studies, the potential role 
of the neuroprotective cytokine insulin-like growth factor-1 (IGF-1) has been investigated. 
Low IGF-1 levels have been associated with delirium in acutely ill elderly patients [8, 19, 
20].
In the present study, we investigated levels of the potential biomarkers neopterin, IL-6 
and IGF-1 in elderly patients with and without a delirium.
PATIENTS AND METHODS
Participants
In this study, we included patients admitted to the wards of Internal Medicine and Geri-
atrics of the Erasmus Medical Center and the ward of Geriatrics of the Harbor Hospital, 
Rotterdam, the Netherlands.
All acutely admitted patients aged t 65 years were eligible to participate in the study. 
Exclusion criteria were a diagnosis of Lewy body dementia, Parkinson’s disease, neuroleptic 
malignant syndrome, tardive dyskinesia, ongoing treatment with antipsychotics or other 
Chapter 2.1
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psychiatric medications except haloperidol and benzodiazepines, aphasia, insufﬁcient un-
derstanding of the Dutch language and a Mini-Mental State Examination (MMSE) score < 
10.
Written informed consent was obtained from all participants. In case of a delirium or 
cognitive impairment at the time of admission, informed consent was obtained from a rep-
resentative of the patient. The Medical Ethics Committee of the Erasmus Medical Center 
approved the study protocol.
Procedures
All participants were observed daily by the nursing and medical staff and by members 
of the research team until discharge. To screen for a change in behavior, the 13-items 
Delirium Observation Screening scale was used during the ﬁrst 5 days of admission [21]. 
The diagnosis of delirium was made by a geriatrician, according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [1], and was based on the 
psychiatric examination of the patient, the medical and nursing records, including the 
Delirium Observation Screening scale scores, and information given by the patient’s closest 
relative. When the diagnosis of delirium was doubtful, the case was discussed with the 
geriatric consultation team to gain consensus.
Demographic and clinical data were collected at admission. Age, sex and living situation 
before admission were documented. Cognitive functioning was assessed in absence of a 
delirium using the MMSE [22]. When it was impossible to score the MMSE during admission 
because the patient was too ill, the cognitive functioning was discussed with a clinician 
or assessed with information from the available medical records. When there was enough 
evidence that the patient would have a MMSE score t 10, the patient was not excluded 
from the study. Severity of comorbidities was scored using the Charlson Comorbidity Index 
[23]. The physical functionality was assessed using the 6-items Katz Activities of Daily Liv-
ing (ADL) scale and the Barthel Index [24, 25]. The instrumental functionality was assessed 
using the 7-items Older Americans Resource Scale for Instrumental ADL [24]. The frailty 
of the patients was measured with the Identiﬁcation Seniors at Risk questionnaire [26]. 
Blood samples of all patients were collected within 48 h after admission. When a patient 
developed a delirium during the hospital stay, new blood samples were collected within 24 
h after the onset of the delirium and were used for the statistical analyses.
Biochemical measurements
Nonfasting blood was collected preferably between 8 and 10 a.m. in a 8-ml tube contain-
ing ethylene diamine tetra-acetic acid as well as in a 10-ml serum-separating tube. After 
blood sampling, the tubes were stored at room temperature and protected from light to 
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prevent oxidative loss of neopterin [27]. Within 3 h, the blood was centrifuged for 20 min 
at 2,650 g and 20 °C. The obtained plasma and serum were stored at –80 °C until analysis.
Plasma neopterin levels were determined by high-performance liquid chromatography 
after acid oxidation, as previously described [28]. The Human IL-6 Chemi Enzyme-Linked 
Immunosorbent Assay Kit (Invitrogen™, Life Technologies, Carlsbad, Calif., USA) was used 
for the quantiﬁcation of serum IL-6 levels. Serum levels of IGF-1 were determined by the 
IMMULITE® 2000 Analyzer (Siemens Healthcare, Erlangen, Germany).
C-reactive protein (CRP) levels and the estimated glomerular ﬁltration rate (eGFR) were 
taken from the medical records. These markers were used to adjust neopterin for inﬂam-
matory state and renal function. The eGFR was determined by the following Modiﬁcation 
of Diet in Renal Disease formula: 175 × [serum creatinine (μmol/l) × 0.0113]−1.154 × age−0.203 
× 0.742 (if female).
Statistical analysis
Medians and interquartile ranges were determined for continuous participant characteris-
tics and proportions for categorical characteristics. Biochemical parameters with a skewed 
distribution were logarithmically transformed (neopterin, IL-6, IGF-1 and CRP). Univari-
ate one-way analysis of variance was used to investigate the association between mean 
levels of neopterin, IL-6, CRP, eGFR and IGF-1 (dependent variable) and the presence of 
a delirium. Models were adjusted for age, sex and the Charlson Comorbidity Index, and 
those including neopterin were adjusted for age, sex, Charlson Comorbidity Index, tertiles 
of eGFR and additionally for CRP levels. Mean eGFR values in the tertiles were 34.5, 57.4 
and 96.5 ml/min. Additional analyses were performed for neopterin, IL-6 and IGF-1 after 
adding also MMSE score to the models. A two-tailed p < 0.05 was deﬁned as statistically 
signiﬁcant.
Univariate one-way analysis of variance was used to compare mean neopterin levels 
across tertiles of eGFR. Nonlinear regression was used to ﬁt a two-phase exponential decay 
model to the eGFR values and corresponding neopterin levels.
GraphPad Prism 5.01 for Windows (GraphPad Software, San Diego, Calif., USA) was used 
for curve ﬁtting and to draw all graphs. Statistical Package for the Social Sciences, version 
21.0 (SPSS Inc., Chicago, Ill., USA) was used to perform the other statistical analyses.
Chapter 2.1
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RESULTS
Participant characteristics
Table 1 represents the baseline characteristics of the 86 participants who were included 
in the study. Twenty-three patients were diagnosed with a delirium, of which 21 were 
admitted to the hospital with a delirium and 2 developed a delirium during admission.
Table 1. Characteristics of the study participants
No delirium (n = 63) Delirium (n = 23)
Male 47.6 43.5
Age, years 81.0 (75.0–85.0) 87.0 (84.0–88.0)
MMSE score 25.5 (22.0–28.0) a 20.0 (18.0–25.0) b
Living situation
Home 47.6 26.1 
Home care 31.7 30.4 
Residential home 7.9 17.4 
Nursing home 3.2 13.0 
Missing data 9.5 13.0 
Katz ADL score 0.0 (0.0–3.0) 2.0 (1.0–11.0)
OARS-IADL score 5.0 (0.0–10.0) 9.5 (3.5–14.0)
Barthel Index 18.0 (13.0–20.0) 16.0 (9.5–19.0)
ISAR score 4.0 (2.0–6.0) 6.0 (4.8–7.0)
Charlson Comorbidity Index 1.0 (1.0–2.0) 2.0 (1.0–3.0)
Notes: Values are expressed as median (interquartile range) or percentages. a Three values missing. b 
Four values missing.
Abbreviations: ADL, Activities of Daily Living; ISAR, Identiﬁcation of Seniors at Risk; MMSE, Mini-Men-
tal State Examination; OARS-IADL, Older Americans Resource Scale for Instrumental Activities of Daily 
Living.
Analyses of biochemical parameters
Mean levels and corresponding 95% conﬁdence intervals (CI) of the investigated biochemi-
cal parameters in patients with and without a delirium are presented in table 2. In adjusted 
models, mean neopterin levels were signiﬁcantly higher in patients with a delirium (70.5 
nmol/l, 95% CI: 54.1–91.8) than in those without (45.9 nmol/l, 95% CI: 39.4–53.6) (p = 
0.009; ﬁgure 1A). This association remained statistically signiﬁcant after additional adjust-
ment for CRP levels. For 6 patients, IL-6 data were missing (delirium, n = 1; no delirium, n = 
5). Mean IL-6 levels were signiﬁcantly higher in patients with a delirium (43.1 pg/ml, 95% 
CI: 22.5–82.2) compared to those without (18.5 pg/ml, 95% CI: 12.6–27.2) (p = 0.034; 
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ﬁgure 1B). Mean IGF-1 levels were signiﬁcantly lower in patients with a delirium (6.3 
nmol/l, 95% CI: 5.0–8.0) than in those without a delirium (9.3 nmol/l, 95% CI: 8.1–10.7) 
(p = 0.007; ﬁgure 1C). In all additional models adjusted for MMSE score, estimates re-
mained statistically signiﬁcant (data not shown).
Tertiles of eGFR were associated with decreasing neopterin levels (ﬁgure 2). In the ﬁrst 
tertile, the mean neopterin level was 78.3 nmol/l (95% CI: 61.5–99.8), in the second, 
44.8 nmol/l (95% CI: 35.4–56.5) and in the third, 39.4 nmol/l (95% CI: 30.8–50.1). Mean 
neopterin levels were signiﬁcantly lower in the second (p = 0.001) and third tertile (p = 
0.000) than in the ﬁrst tertile. Figure 3 shows the two-phase exponential decay curve for 
neopterin levels as function of eGFR.
DISCUSSION
In the present study, we found elevated mean levels of neopterin and IL-6 as well as 
reduced mean levels of IGF-1 in elderly patients with a delirium. We found that patients 
with a delirium have increased neopterin levels, even after adjustment for inﬂammatory 
state. Since neopterin levels may reﬂect the amount of cell-mediated immune activation 
and oxidative stress [10, 11], this ﬁnding might suggest that oxidative stress plays the most 
important role in the induction of delirium and that cellular immune activation is not a 
prerequisite for delirium. In the present study, we also found that patients with a severe 
impaired renal function have signiﬁcantly increased neopterin levels compared to patients 
with a less impaired renal function. This ﬁnding is in agreement with the study by Godai et 
al. [29], in which a negative exponential correlation was found between serum neopterin 
levels and creatinine clearance in younger individuals without an infection. The effect of 
Table 2. Mean levels of biochemical parameters
No delirium (n = 63) Delirium (n = 23) p-value
Neopterin, nmol/l a 45.9 (39.4–53.6) 70.5 (54.1–91.8) 0.009
Neopterin, nmol/l a,b 47.6 (41.8–54.3) 64.7 (51.5–81.1) 0.028
IL-6, pg/ml a 18.5 (12.6–27.2) 43.1 (22.5–82.2) 0.034
CRP, mg/l a 18.5 (12.0–28.6) 33.0 (15.8–69.2) 0.196
eGFR, ml/min 65.4 (59.1–71.8) 53.9 (43.0–64.8) 0.081
IGF-1, nmol/l a 9.3 (8.1–10.7) 6.3 (5.0–8.0) 0.007
Notes: Values are expressed as mean (95% conﬁdence interval). Models are adjusted for age, sex and 
Charlson Comorbidity Index. Models including neopterin are adjusted for age, sex, Charlson Comorbid-
ity Index and eGFR. a Means and 95% conﬁdence intervals are the back-transformed log10-values. b Ad-
ditionally adjusted for log CRP.
Abbreviations: CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; IGF-1, insulin-like 
growth factor-1; IL-6, interleukin-6.
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renal function on neopterin levels has probably not inﬂuenced our results, since neopterin 
levels were adjusted for eGFR. Our ﬁnding of increased neopterin levels in elderly patients 
with a delirium is in agreement with the elevated neopterin levels that have previously 
been found by Osse et al. [6] in patients with a postoperative delirium.
Furthermore, we found that patients with a delirium have elevated serum IL-6 levels, 
suggesting an activated immune system. This ﬁnding is in line with previous results found 
in medical and surgical patients with a delirium [15-17]. Our results also showed that 
patients with a delirium have reduced serum IGF-1 levels. Since IGF-1 is a neuroprotective 
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Figure 1. Mean levels and corresponding 95% conﬁdence intervals of neopterin (A), interleukin-6 (B) 
and IGF-1 (C) in patients with and without a delirium.
Abbreviation: IGF-1, insulin-like growth factor-1.
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cytokine that is able to pass the blood-brain barrier [30], this ﬁnding might suggest a loss 
of brain reserve. Our ﬁnding is in agreement with earlier results found in elderly patients 
who were acutely admitted to the hospital [8, 20].
Our results of elevated levels of neopterin and IL-6 and reduced levels of IGF-1 in patients 
with a delirium might suggest that a disturbed activation of the innate and cellular im-
mune system, oxidative stress and an increased vulnerability of the brain may underlie the 
development of a delirium. It is, however, unclear whether neopterin plays a direct role in 
the pathogenesis of delirium or that it reﬂects the involvement of other factors. In various 
diseases with neurological complications, such as multiple sclerosis and HIV infection with 
the AIDS dementia complex, elevated neopterin levels have been found in cerebrospinal 
ﬂuid [31, 32]. The source of neopterin in cerebrospinal ﬂuid in these diseases remains 
unclear, but an in vitro study has suggested that neopterin in the brain might derive from 
inﬁltrating macrophages and monocytes, since astrocytes, microglia and neurons were 
not able to produce neopterin [33]. The same study also showed that neopterin itself had 
no effect on the viability of brain cells, but its derivative 7,8-dihydroneopterin was able 
to induce apoptosis in astrocytes and neurons in a dose-dependent manner [33]. It might 
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Figure 2. Mean levels and corresponding 95% conﬁdence intervals of neopterin by tertiles of the esti-
mated glomerular ﬁltration rate (eGFR).
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Figure 3. Two-phase exponential decay curve of neopterin levels as function of the estimated glomerular 
ﬁltration rate (eGFR).
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be possible that neopterin is associated with delirium through the indirect induction of 
apoptosis in the brain.
A second mechanism exists that might explain why high neopterin levels are related 
to delirium. Interferon-gamma stimulates not only the enzyme guanosine triphosphate 
cyclohydrolase-I in macrophages [10, 11], which causes the production of neopterin, but 
also the enzyme indoleamine 2,3-dioxygenase [34]. This enzyme is part of the kynurenine 
pathway, and under normal circumstances, nearly 90% of the amino acid tryptophan is 
metabolized via this pathway. Induction of indoleamine 2,3-dioxygenase is responsible 
for an increased metabolism of tryptophan to kynurenine both in peripheral and central 
tissue. Kynurenine is able to pass the blood-brain barrier and can be further metabolized 
to kynurenic acid and quinolinic acid. The latter is a neurotoxic metabolite produced by 
microglia, which may cause a delirium [34, 35].
It might be possible that in some patients elevated IL-6 levels played a role in the devel-
opment of a delirium. This cytokine may activate astrocytes and microglial cells, which in 
turn produce neurotoxic factors and pro-inﬂammatory cytokines [36, 37]. These factors 
may decrease synaptic plasticity and cholinergic neurotransmission in the brain [36, 37]. 
A central cholinergic deﬁciency is one of the most hypothesized causes of a delirium [38].
Our results also show that patients with a delirium have reduced IGF-1 levels. This neuro-
protective cytokine inhibits oxidative stress and promotes neuronal survival [30]. Therefore, 
low IGF-1 levels might suggest that the brain is more vulnerable to the cytotoxic effects of 
cytokines and other neurotoxic factors [20], for example, IL-6 and quinolinic acid.
Our hypothesized mechanisms by which neopterin, IL-6 and IGF-1 are involved in the 
pathogenesis of a delirium might all suggest neuronal injury. This hypothesis is in line with 
results of previous studies, which showed that S100B, a marker of cerebral damage, is 
elevated in the serum of patients with a delirium [39, 40]. Neuronal injury might also be an 
explanation for the severe complications seen after a delirium and for the association of a 
delirium with dementia [3, 18].
Limitations and strengths
This study has some limitations. First, our ﬁndings were obtained in a relatively small group 
of patients; therefore, extrapolation to a larger population needs to be further investigated. 
Second, the timing of blood sampling might be a factor of signiﬁcance. It is possible that 
the levels of the biochemical markers are dependent on the delirium duration and severity. 
However, we were not able to adjust for these two factors (delirium severity was not 
scored). Besides, it is possible that biomarker levels will ﬂuctuate during the day in patients 
with a delirium, just like delirium symptoms. In the present study, blood sampling and 
delirium occurred on the same day. However, there is a possibility that the patients had no 
delirium symptoms at the moment of blood sampling. These factors might have inﬂuenced 
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our results. Third, it might be speculated that comorbidities might have inﬂuenced the 
mean levels of biomarkers; however, also after adjustment for Charlson Comorbidity Index, 
estimates remained statistically signiﬁcant. Finally, some patients were not included in the 
study and this might have resulted in some selection bias. However, since this was random 
(both in patients and controls) we think that our results are only minimally inﬂuenced by 
this.
The strengths of the present study are as follows. First, the intensive monitoring of 
clinical symptoms of patients with a delirium until discharge and the DSM-IV diagnosis by 
a geriatrician makes it less likely that we missed a delirium or misdiagnosed symptoms. 
Second, we did not focus on one but on several possible pathways that might lead to 
a delirium as it has been suggested that the pathophysiology is multifactorial. Third, to 
the best of our knowledge, the potential role of neopterin in delirium has never been 
investigated in elderly patients admitted due to acute pathology.
CONCLUSION
In this study, we found that patients with a delirium had higher levels of neopterin and IL-6 
and lower levels of IGF-1 than patients without a delirium. These results might suggest a 
potential role of neopterin, IL-6 and IGF-1 in the pathophysiology of a delirium in elderly 
patients. However, the pathways by which these biomarkers are associated with a delirium 
remain speculative and require further investigation. Moreover, larger studies are needed 
to investigate the clinical signiﬁcance of plasma neopterin as a biomarker for delirium 
diagnosis next to, or instead of, peripheral levels of IL-6 and IGF-1.
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ABSTRACT
Background/Aim
Oxidative stress and disturbances in serotonergic and dopaminergic neurotransmission 
may play a role in the pathophysiology of delirium. In this study, we investigated levels 
of amino acids, amino acid ratios and levels of homovanillic acid (HVA) as indicators for 
oxidative stress and disturbances in neurotransmission.
Methods
Plasma levels of amino acids, amino acid ratios and HVA were determined in acutely ill 
patients aged t 65 years admitted to the wards of Internal Medicine and Geriatrics of 
the Erasmus University Medical Center and the ward of Geriatrics of the Harbor Hospital, 
Rotterdam, the Netherlands. Differences in the biochemical parameters between patients 
with and without delirium were investigated by analysis of variance in models adjusted for 
age, sex and comorbidities.
Results
Of the 86 patients included, 23 had delirium. In adjusted models, higher mean phenylala-
nine/tyrosine ratios (1.34 vs. 1.14, p = 0.028), lower mean tryptophan/large neutral amino 
acids ratios (4.90 vs. 6.12, p = 0.021) and lower mean arginine levels (34.8 vs. 45.2 μmol/l, 
p = 0.022) were found in patients with delirium when compared to those without. No 
differences were found in HVA levels between patients with and without delirium.
Conclusion
The ﬁndings of this study suggest disturbed serotonergic neurotransmission and an in-
creased status of oxidative stress in patients with delirium.
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INTRODUCTION
Delirium is a common and severe complication among elderly patients and is associated 
with increased morbidity and mortality, prolonged hospital stay, increased risk of post-
discharge institutionalization and dementia [1, 2]. The pathophysiology of delirium is still 
largely hypothetical. Identifying accurate biomarkers for delirium may shed light on the 
pathophysiology and may help to improve delirium recognition and care.
Oxidative stress and disturbances in serotonergic and dopaminergic neurotransmission 
might all be involved in the pathophysiology of delirium and probably act together [3]. 
Within the central nervous system, tetrahydrobiopterin (BH4) functions as an essential 
cofactor in enzymatic reactions responsible for the production of serotonin and dopamine. 
In addition, BH4 is a cofactor for nitric oxide synthase (NOS) that catalyzes the production 
of nitric oxide (NO) and citrulline from arginine [4]. If BH4 becomes limited, this could 
impair serotonin and dopamine synthesis. Besides, when BH4 is partially deﬁcient, some 
cellular sources of NOS may generate superoxide (O2s−) instead of NO and citrulline [4, 
5]. In patients with delirium, BH4 status has only been investigated after elective cardiac 
surgery [6].
In order to assess BH4 status, we measured amino acid levels and subsequently calculated 
the phenylalanine/tyrosine (Phe/Tyr) ratio. This ratio is an indicator for the BH4 status as it 
reﬂects the activity of the enzyme Phe hydroxylase, an enzyme that uses BH4 as a cofac-
tor [4, 7]. An elevated ratio is suggestive for decreased BH4 availability. Furthermore, we 
determined the ratios of tryptophan (Trp), Phe and Tyr to the other large neutral amino 
acids (LNAAs). Trp is the precursor of serotonin, while Phe and Tyr are the precursors of 
dopamine. The LNAAs (Trp, Phe, Tyr, valine, isoleucine and leucine) compete with each 
other for transport across the blood-brain barrier. Therefore, a decreased Trp/LNAAs ratio 
is suggestive for a decline in the amount of Trp that enters the brain and consequently for 
reduced synthesis of serotonin [8]. Moreover, we measured plasma levels of the dopamine 
metabolite homovanillic acid (HVA), approximately 30% of which is estimated to originate 
from dopamine neurons in the central nervous system and which is therefore thought to 
be a reliable indicator for central dopamine activity [9]. Finally, we measured plasma levels 
of arginine and citrulline to investigate the production of NO by NOS.
The aim of the study was to investigate BH4 status, potential disturbances in serotoner-
gic and dopaminergic neurotransmission and the production of NO in patients with and 
without delirium.
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METHODS
Study design and participants
The present study was performed within the Delirium In The Old (DITO) study in which 
mean levels of neopterin, interleukin-6 and insulin-like growth factor-1 were compared 
between patients with and without delirium [10]. In the DITO study, a cross-sectional study, 
we included patients who were admitted to the wards of Internal Medicine and Geriatrics 
of the Erasmus University Medical Center and the ward of Geriatrics of the Harbor Hospital, 
Rotterdam, the Netherlands. All acutely admitted patients aged t 65 years were eligible to 
participate. Exclusion criteria were a diagnosis of Lewy body dementia, Parkinson’s disease, 
neuroleptic malignant syndrome, tardive dyskinesia, ongoing treatment with antipsychot-
ics or other psychiatric medications except haloperidol and benzodiazepines, aphasia, 
insufﬁcient understanding of the Dutch language and a Mini-Mental State Examination 
(MMSE) score < 10 points out of 30. We excluded patients with a MMSE < 10 because it 
can be quite difﬁcult to distinguish between features of severe dementia and delirium at 
admission as well as to measure improvement of cognitive function in this group.
Written informed consent was obtained from all participants. In case of delirium or 
cognitive impairment at the time of admission, informed consent was obtained from a 
representative of the patient. The Medical Ethics Committee of the Erasmus University 
Medical Center approved the study protocol.
Procedures
All participants were observed daily by the nursing and medical staff and by members 
of the research team until discharge. To screen for a change in behavior, the 13-item 
Delirium Observation Screening scale was used during the ﬁrst 5 days of admission [11]. 
The diagnosis of delirium was made by a geriatrician, according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [12], and was based on the 
psychiatric examination of the patient, the medical and nursing records, including the 
Delirium Observation Screening scale scores, and information given by the patient’s closest 
relative. When the diagnosis of delirium was doubtful, the case was discussed with the 
geriatric consultation team to gain consensus.
Demographic and clinical data were collected at admission. Age, sex and living situation 
before admission were documented. Cognitive functioning was assessed in absence of 
delirium using the MMSE [13]. When it was impossible to score the MMSE during admis-
sion because the patient was too ill, cognitive function was discussed with a clinician or 
assessed with information from the available medical records. When the clinical opinion 
was that the patient would have a MMSE score t 10, the patient was not excluded from 
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the study. Severity of comorbidities was scored using the Charlson Comorbidity Index. 
This index encompasses 19 medical conditions, including dementia, and each condition 
is weighted with a score of 1–6 by severity [14]. Physical functionality was assessed using 
the 6-item Katz Activities of Daily Living scale and the Barthel index [15, 16]. Instrumental 
functionality was assessed using the 7-item Older Americans Resource Scale for Instrumen-
tal Activities of Daily Living [15]. Frailty was measured with the Identiﬁcation of Seniors 
at Risk questionnaire [17]. Blood samples of all patients were collected within 48 h after 
admission. When a patient developed delirium during the hospital stay, new blood samples 
were collected within 24 h after the onset of the delirium and were used instead of the ﬁrst 
blood samples for the statistical analyses.
Biochemical measurements
Nonfasting blood was collected preferably between 8 and 10 a.m. in an 8-ml tube contain-
ing ethylene diamine tetra-acetic acid. After blood sampling, the tubes were stored at 
room temperature to prevent changes in the transfer of amino acids between plasma and 
blood cells [18]. Within 3 h, the blood was centrifuged for 20 min at 2,650 g and 20 °C. 
The obtained plasma was stored at –80 °C until analysis.
Plasma amino acid levels were determined by high-performance liquid chromatogra-
phy with automated pre-column derivatization with ortho-phthalaldehyde as previously 
described [18]. Plasma HVA levels were determined by reversed-phase high-performance 
liquid chromatography and electrochemical detection, as previously described for the 
determination of serotonin [19].
Statistical analysis
Medians and interquartile ranges were determined for continuous participant characteris-
tics and proportions for categorical characteristics. Biochemical parameters with a skewed 
distribution were logarithmically transformed (all amino acids, amino acid ratios and HVA). 
Univariate one-way analysis of variance was used to investigate the association between 
mean levels of amino acids, amino acid ratios and HVA (dependent variables) and the pres-
ence of delirium. Models were adjusted for age, sex and the Charlson Comorbidity Index. 
Additional analyses were performed for all amino acids, amino acid ratios and HVA after 
also adding MMSE score to the models. A two-tailed p < 0.05 was deﬁned as statistically 
signiﬁcant.
Statistical Package for the Social Sciences, version 21.0 (SPSS Inc., Chicago, Ill., USA) 
was used to perform the statistical analyses. GraphPad Prism 5.01 for Windows (GraphPad 
Software, San Diego, Calif., USA) was used to draw all graphs.
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RESULTS
Participant characteristics
Table 1 presents the baseline characteristics of the 86 participants who were included in 
the study. Of the 23 patients diagnosed with delirium, 21 were admitted to the hospital 
with delirium and 2 developed delirium during admission.
Table 1. Characteristics of the study participants
No delirium (n = 63) Delirium (n = 23)
Male 47.6% 43.5%
Age, years 81.0 (75.0–85.0) 87.0 (84.0–88.0)
MMSE score a 25.5 (22.0–28.0) b 20.0 (18.0–25.0) c
Living situation:
 Home 47.6% 26.1% 
 Home care 31.7% 30.4% 
 Residential home 7.9% 17.4% 
 Nursing home 3.2% 13.0% 
 Missing data 9.5% 13.0% 
Katz Activities of Daily Living score d 0.0 (0.0–3.0) 2.0 (1.0–11.0)
OARS-IADL score e 5.0 (0.0–10.0) 9.5 (3.5–14.0)
Barthel Index f 18.0 (13.0–20.0) 16.0 (9.5–19.0)
Identiﬁcation of Seniors at Risk score g 4.0 (2.0–6.0) 6.0 (4.8–7.0)
Charlson Comorbidity Index h 1.0 (1.0–2.0) 2.0 (1.0–3.0)
Notes: Values are expressed as medians (interquartile ranges) or percentages. a Range 0 (severe cognitive 
impairment) to 30 (no cognitive impairment). b Three values missing. c Four values missing. d Range 0 
(no disability) to 12 (severe disability). e Range 0 (no disability) to 14 (severe disability). f Range 0 (severe 
disability) to 20 (no disability). g Scores t 2 indicate a high risk of functional decline. h Range 0–37 (severe 
burden of comorbidities).
Abbreviations: MMSE, Mini-Mental State Examination; OARS-IADL, Older Americans Resource Scale 
for Instrumental Activities of Daily Living.
Analyses of biochemical parameters
The mean levels and corresponding 95% conﬁdence intervals (CIs) of the investigated 
biochemical parameters in patients with and without delirium are presented in tables 2 
and 3. In adjusted models, mean levels of arginine were signiﬁcantly lower in patients 
with delirium (34.8 μmol/l, 95% CI: 28.8–42.0) than in those without (45.2 μmol/l, 95% 
CI: 40.6–50.5) (p = 0.022; ﬁgure 1). Concerning the amino acid ratios, mean Phe/Tyr 
ratios were signiﬁcantly higher in patients with delirium (1.34, 95% CI: 1.19–1.51) than 
in patients without delirium (1.14, 95% CI: 1.06–1.22) (p = 0.028; ﬁgure 1). In addition, 
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mean Trp/LNAAs ratios were signiﬁcantly lower in patients with delirium (4.90, 95% CI: 
4.19–5.74) than in those without (6.12, 95% CI: 5.58–6.71) (p = 0.021; ﬁgure 1). No 
associations between the other amino acids and ratios and delirium were found, although 
citrulline (ﬁgure 1) and Trp levels were at the border of signiﬁcance lower in patients with 
delirium than in those without (p = 0.052 and p = 0.067, respectively).
Table 2. Mean levels of amino acids
No delirium (n = 63) Delirium (n = 23) p-value
Glutamic acid, μmol/l 46.2 (40.9–52.2) 41.3 (33.5–50.9) 0.368
Serine, μmol/l 84.5 (78.7–90.8) 81.3 (71.9–91.8) 0.596
Glycine, μmol/l 194.5 (179.5–210.9) 187.1 (162.6–214.8) 0.633
Citrulline, μmol/l 29.4 (26.1–33.3) 23.0 (18.6–28.4) 0.052
Arginine, μmol/l 45.2 (40.6–50.5) 34.8 (28.8–42.0) 0.022
Alanine, μmol/l 329.6 (297.1–364.8) 337.3 (283.1–402.7) 0.814
Taurine, μmol/l 41.3 (37.4–45.5) 38.5 (32.6–45.6) 0.496
Tyrosine, μmol/l 58.6 (54.0–63.7) 55.6 (48.2–64.1) 0.529
Valine, μmol/l 212.8 (198.2–228.0) 214.8 (190.5–241.5) 0.898
Methionine, μmol/l 22.4 (20.8–24.3) 23.3 (20.4–26.5) 0.651
Tryptophan, μmol/l 32.1 (28.8–35.7) 26.2 (21.8–31.5) 0.067
Phenylalanine, μmol/l 66.7 (62.2–71.4) 74.5 (66.2–83.8) 0.122
Isoleucine, μmol/l 59.6 (55.0–64.6) 57.7 (50.2–66.2) 0.690
Leucine, μmol/l 120.5 (111.4–130.6) 123.3 (107.6–141.3) 0.783
Ornithine, μmol/l 78.0 (71.0–85.5) 67.6 (57.5–79.4) 0.146
Notes: Values are expressed as means (95% conﬁdence intervals) and are the back-transformed log10 
values. Models are adjusted for age, sex and Charlson Comorbidity Index.
Table 3. Mean levels of amino acid ratios and homovanillic acid
No delirium (n = 63) Delirium (n = 23) p-value
Phe/Tyr ratio 1.14 (1.06–1.22) 1.34 (1.19–1.51) 0.028
Trp/LNAAs ratio (x 100) 6.12 (5.58–6.71) 4.90 (4.19–5.74) 0.021
Tyr/LNAAs ratio (x 100) 11.8 (11.0–12.7) 11.0 (9.7–12.4) 0.342
Phe/LNAAs ratio (x 100) 13.6 (12.7–14.7) 15.3 (13.6–17.3) 0.122
HVA, nmol/l 93.3 (79.4–109.4) a 123.0 (93.3–162.6) a 0.098
Notes: Values are expressed as means (95% conﬁdence intervals) and are the back-transformed log10 
values. Models are adjusted for age, sex and Charlson Comorbidity Index. a One value missing.
Abbreviations: HVA, homovanillic acid; LNAAs, large neutral amino acids; Phe, phenylalanine; Trp, 
tryptophan; Tyr, tyrosine.
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Figure 1. Mean levels and corresponding 95% conﬁdence intervals of the Phe/Tyr ratio (A), the Trp/
LNAAs ratio (B), arginine (C) and citrulline (D) in patients with and without delirium.
Abbreviations: LNAAs, large neutral amino acids; Phe, phenylalanine; Trp, tryptophan; Tyr, tyrosine.
HVA data were missing for 2 patients (delirium, n = 1 [not enough plasma]; no delirium, 
n = 1 [measurement failed]). Mean HVA levels were not statistically signiﬁcantly different 
between patients with delirium (123.0 nmol/l, 95% CI: 93.3–162.6) and patients without 
delirium (93.3 nmol/l, 95% CI: 79.4–109.4) (p = 0.098).
In the models additionally adjusted for MMSE score, the association between arginine 
and delirium did not reach statistical signiﬁcance (delirium: mean 36.0 μmol/l, 95% CI: 
28.7–45.1 vs. no delirium: mean 44.8 μmol/l, 95% CI: 39.8–50.5, p = 0.107). Mean Phe/
Tyr ratios remained borderline signiﬁcantly higher in patients with delirium (1.34, 95% 
CI: 1.16–1.55) than in those without (1.15, 95% CI: 1.07–1.24) (p = 0.089) and mean 
Trp/LNAAs ratios remained borderline signiﬁcantly lower in patients with delirium (5.00, 
95% CI: 4.15–6.01) compared to those without (6.15, 95% CI: 5.58–6.78) (p = 0.062). 
Estimates for the other biochemical parameters remained statistically insigniﬁcant (data 
not shown).
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DISCUSSION
In the present study, we found disturbed serotonergic neurotransmission and an increased 
status of oxidative stress in patients with delirium when compared to patients without 
delirium.
As far as we are aware, this is the ﬁrst delirium study investigating BH4 status and levels 
of arginine and citrulline in acutely ill elderly hospitalized patients. In order to assess the 
BH4 status, we measured the Phe/Tyr ratio. In patients with delirium, we found an increased 
ratio, suggesting a deﬁciency in the essential cofactor BH4 for the production of serotonin, 
dopamine and NO. Decreased BH4 availability has already been found in other neuropsychi-
atric disorders such as Alzheimer’s disease [20], Parkinson’s disease [20] and schizophrenia 
[21]. Our ﬁnding is not in agreement with the results of a previous delirium study which 
showed that levels of BH4 and Phe/Tyr ratios did not differ between patients with and 
without delirium [6]. However, that study included a relatively younger group of patients 
undergoing elective cardiac surgery.
In the present study, serotonergic neurotransmission was investigated with the Trp/
LNAAs ratio and the Phe/Tyr ratio. We found that patients with delirium had a decreased 
Trp/LNAAs ratio, which might suggest reduced serotonin production in the central nervous 
system. This hypothesis is strengthened by the ﬁnding that patients with delirium had an 
elevated Phe/Tyr ratio, which might suggest a deﬁciency in the essential cofactor BH4 in 
the production of serotonin. In previous studies, controversial results have been reported. 
Several studies found a reduced Trp/LNAAs ratio during delirium [6, 8, 22, 23], whereas 
two studies reported no difference in this ratio between patients with and without delirium 
[24, 25]. The study performed by Flacker and Lipsitz [24] included only patients with mild 
illnesses not requiring hospitalization. Therefore, the ﬁndings may not be generalizable 
to acutely ill patients who needed medical care in hospital. The study performed by van 
der Cammen et al. [25] included delirium patients with Alzheimer’s disease. It might be 
possible that in those patients a disturbance in cholinergic neurotransmission played a 
more important role in the development of delirium than disturbances in other pathophysi-
ological pathways [26].
Furthermore, we found no differences in Phe/LNAAs ratios, Tyr/LNAAs ratios and HVA 
levels between patients with and without delirium, suggesting that dopaminergic neuro-
transmission is not impaired during delirium. The ﬁnding that plasma HVA levels are not 
signiﬁcantly increased in patients with delirium compared to patients without delirium is 
not in agreement with earlier results [6, 25]. However, those studies were performed in 
patients with Alzheimer’s disease [25] and patients undergoing cardiac surgery [6], and 
therefore the results may not be generalizable. Ramirez-Bermudez et al. [27] found that 
cerebrospinal ﬂuid HVA levels correlated with psychotic symptoms of delirium (hallucina-
tions and delusions) in neurological patients. It might also be possible that we did not ﬁnd 
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an association between the dopaminergic markers and the presence of delirium because 
we included patients both with and without psychotic features.
In our study, we also found reduced plasma arginine levels and borderline statistically 
signiﬁcantly reduced citrulline levels in patients with delirium. Considering the cross-sectional 
study design, these ﬁndings could mean several things. First, it is possible that patients with 
delirium had a pre-existing arginine deﬁciency which might have resulted in a reduced produc-
tion of citrulline by NOS (ﬁgure 2A). Second, when BH4 is partially deﬁcient, as our results do 
suggest, some cellular sources of NOS may generate O2s− instead of citrulline and NO from 
arginine (ﬁgure 2B) [4, 5], leading to decreased levels of both arginine and citrulline. If this 
latter scenario is true for delirium, this would also suggest an increased status of oxidative 
stress, since it favors peroxynitrite formation (ﬁgure 2B). If peroxynitrite is not scavenged by 
antioxidants, it may cause oxidative damage to cellular macromolecules [20, 28], which has 
already been hypothesized to occur in Alzheimer’s disease [29]. However, both amino acids 
have been investigated previously by Osse et al. [6] in patients with delirium after cardiac 
surgery, but they found no differences in arginine and citrulline levels between patients with 
and without delirium. Since they also reported no difference in BH4 status between patients 
with and without delirium, the results are probable not generalizable to our study.
B. BH decreased 
Arginine 
Citrulline NO OŞí 
ONOOí
(peroxynitrite) 
Oxidative damage 
BH  
NOS 
     Arginine 
  Citrulline    NO 
BH 
NOS 
A. BH normal 
Figure 2. Schematic presentation of the role of tetrahydrobiopterin (BH4) in the formation of citrulline, 
nitric oxide (NO) and superoxide (O2s−) by nitric oxide synthase (NOS). A. Situation in which there is 
sufﬁcient supply of BH4 for NOS. B. Situation in which there is insufﬁcient supply of BH4. Some cellular 
sources of NOS will generate O2s− instead of NO and citrulline. Generation of O2s− and NO together will 
lead to the formation of peroxynitrite, which may cause oxidative damage.
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Limitations and strengths
This study has some limitations. First, our ﬁndings were obtained in a relatively small group 
of patients; therefore, conﬁrmation in a larger population is recommended. Second, it 
might be speculated that the degree of the patients’ cognitive functioning inﬂuenced the 
mean levels of the biochemical parameters [20]. In this study, we adjusted for the Charlson 
Comorbidity Index, which includes dementia, and our estimates remained statistically 
signiﬁcant. However, for our additional analysis, MMSE scores were not available for all 
patients; therefore, we can neither conﬁrm nor deny that the presence of a comorbid 
cognitive disturbance, not diagnosed as dementia (yet), was a confounding factor. Third, 
the timing of blood sampling might be a factor of signiﬁcance. It is possible that the levels 
of biochemical markers are dependent on delirium duration and severity or even ﬂuctuate 
during the day in patients with delirium, just like delirium symptoms. In the present study, 
blood sampling and delirium occurred on the same day, but there is a possibility that the 
patients had no delirium symptoms at the moment of blood sampling. This might have 
inﬂuenced our results. Finally, some potential participants were not included in the study 
and this may have resulted in some selection bias; however, since this was random and 
occurred in both patients with and without delirium, we think that our results are only 
minimally inﬂuenced by this.
The present study has several strengths. First, the intensive monitoring of clinical symp-
toms of patients with delirium until discharge and the DSM-IV diagnosis by a geriatrician 
makes it less likely that we missed delirium or misdiagnosed symptoms. Second, we did not 
focus on one but on several possible pathways that might lead to delirium as it has been 
suggested that the pathophysiology is multifactorial.
CONCLUSION
In this study in older, acutely ill hospitalized patients, we found that patients with delirium 
had higher Phe/Tyr ratios, lower Trp/LNAAs ratios and lower levels of arginine and citrulline 
than patients without delirium. These ﬁndings might suggest that decreased BH4 avail-
ability, disturbed serotonergic neurotransmission and an increased status of oxidative stress 
may have played a role in the pathogenesis of delirium in our patient group. Since as far as 
we know this is the ﬁrst delirium study investigating BH4 status and levels of arginine and 
citrulline in acutely ill elderly hospitalized patients, conﬁrmation of our results in a larger, 
comparable population is recommended. Moreover, more research is needed to explore 
the potential differences in the pathophysiology of delirium in patients with and without 
cognitive disorders.
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ABSTRACT
Background/Aim
Delirium is a common and severe complication among older hospitalized patients. The 
pathophysiology is poorly understood, but it has been suggested that inﬂammation and 
oxidative stress may play a role. The aim of this pilot study was to investigate levels of 
the neutrophil-lymphocyte ratio (NLR) – a marker of systemic inﬂammation and oxidative 
stress – in patients with and without delirium.
Methods
This pilot study was performed within a retrospective chart review study that included 
acutely ill patients, 65 years and older, who were admitted to the ward of geriatrics of the 
Erasmus University Medical Center. All patients in whom the differential white blood cell 
(WBC) counts as well as the C-reactive protein (CRP) level were determined within 24 h 
after admission were included in the present study. Differences in NLR between patients 
with and without delirium were investigated using univariate analysis of variance, with 
adjustments for age, sex, comorbidities, CRP level and total WBC count.
Results
Eighty-six patients were included. Thirteen patients were diagnosed with delirium. In ad-
justed models, higher mean NLR values were found in patients with delirium than in those 
without delirium (9.10 versus 5.18, p = 0.003).
Conclusion
In this pilot study, we found increased NLR levels in patients with delirium. This ﬁnding 
might suggest that an inadequate response of the immune system and oxidative stress 
may play a role in the pathogenesis of delirium. Further studies are needed to conﬁrm the 
association between NLR and delirium.
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INTRODUCTION
Delirium, an acute neuropsychiatric syndrome, is a common complication among older 
hospitalized persons and is associated with prolonged hospital stay, loss of independence, 
and increased risk of cognitive decline and mortality [1, 2]. The underlying pathophysiology 
is poorly understood and the diagnosis is still primarily based on clinical observation [3]. 
Identifying accurate biomarkers for delirium may shed light on the pathophysiology and 
potentially improve delirium recognition and prediction.
Both inﬂammation and oxidative stress may be involved in the pathophysiology of de-
lirium [4, 5]. Several inﬂammatory markers have been investigated and were found to be 
associated with delirium, but time-consuming and expensive measurements make their use 
for research purposes and clinical practice less attractive.
The neutrophil-lymphocyte ratio (NLR), derived directly from the differential white blood 
cell (WBC) count, is an easily applicable marker of inﬂammation and oxidative stress [6]. 
Several studies have reported an association between increased NLR and cerebrovascular 
disease [7], schizophrenia [6] and Alzheimer’s disease [8] as well as an association with 
increased severity and poor prognosis of various cardiovascular diseases [9-11] and 
malignancies [12]. Furthermore, NLR has been found to be a more powerful predictor 
of cardiovascular risk and mortality in various medical conditions in comparison with 
traditional infection markers, such as the total WBC count, the individual WBC subtypes 
and C-reactive protein (CRP) [13-16]. No previous study has investigated the possible as-
sociation between the NLR and delirium.
We hypothesized that mean NLR levels would be elevated in patients with delirium; 
therefore, in this pilot study, we compared mean NLR levels of patients with and without 
delirium who were acutely admitted to a geriatric ward.
METHODS
The present study was performed within a retrospective chart review study in which the 
possible association between anticholinergic drug exposure and delirium, length of hospi-
tal stay, postdischarge institutionalization and in-hospital mortality was investigated [17]. 
In the previous study, all acutely ill elderly aged 65 and older who were admitted to the 
ward of geriatrics of the Erasmus University Medical Center, Rotterdam, the Netherlands, 
between January 1, 2012 and December 31, 2015 were eligible for inclusion. Acutely ill 
patients were deﬁned as patients with an acute disease whereby a hospital admission was 
required for medical treatment. Patients hospitalized for less than 3 days, admitted for 
elective (diagnostic) procedures, or with missing data on drug use or outcome measures 
were not included [17]. In the present pilot study, we included all patients enrolled in the 
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previous study in whom the differential WBC counts as well as the CRP level were deter-
mined within 24 h after admission. The rationale to choose this time period is that drugs, 
such as antibiotics, started on admission can have a signiﬁcant effect on CRP and WBC 
counts within 48 h. To our knowledge, it is unknown whether NLR levels are stable over 
time in acutely ill patients. To minimize the possible inﬂuence of drugs on the investigated 
markers, the ﬁrst 24 h were chosen as the cut-off.
The study was conducted in accordance with the principles expressed in the Declara-
tion of Helsinki. In the Netherlands, ethical approval is only required for studies in which 
persons are subjected to additional diagnostic procedures or treatments or are required to 
follow a certain behavioral strategy. No ethical approval and patient consent are required 
for retrospective chart review studies in which data collected during routine clinical care are 
extracted and analyzed anonymously.
Data collection
All data were extracted from medical records. Age, sex, place of residence before admis-
sion, and the presence of delirium during the hospital stay were documented. Severity of 
comorbidities on admission was calculated using the Charlson Comorbidity Index (CCI) 
[18]. The total WBC count, neutrophil count, lymphocyte count, and CRP level within 24 
h after admission were recorded. The NLR was calculated by dividing the neutrophil count 
by the lymphocyte count. WBC, neutrophil and lymphocyte counts were determined on 
a Sysmex XN-9000 hematology analyzer with ﬂow cytometry (Sysmex Corporation, Kobe, 
Hyogo Prefecture, Japan). CRP was determined with the CRPL3 assay (immunoturbidimetric 
method) on a Cobas 8000 c701/702 analyzer (Roche Diagnostics, Rotkreuz, Switzerland).
Definition of delirium
Reported diagnoses of delirium were extracted from medical records. On the ward of 
geriatrics, the diagnosis of delirium is made by geriatricians as part of daily clinical practice, 
according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 
4th and 5th editions [19, 20], and is based on daily psychiatric examination, medical and 
nursing notes, the Delirium Observation Screening scale scores, and information given by 
the patient’s closest relative. In the previous chart review study, delirium was deﬁned as 
‘‘present on admission’’ if the diagnosis was made within the ﬁrst 2 days of the hospital 
stay. All other cases of delirium were deﬁned as ‘‘incident delirium’’. In this pilot study, 
these two groups were combined.
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Statistical analysis
Differences in baseline characteristics between patients with and without delirium were 
compared using the Fisher’s exact test for categorical variables, the Mann-Whitney U-test 
for non-normally distributed continuous variables, and the Student’s t-test for normally 
distributed continuous variables.
Univariate one-way analysis of variance was used to compare mean levels of NLR, CRP, 
WBC, neutrophils and lymphocytes in patients with and without delirium. Biochemical 
parameters with a skewed distribution were logarithmically transformed using the natural 
log (NLR, WBC count, neutrophil count and CRP levels). Models were adjusted for age, 
sex, CCI, CRP levels and total WBC count, except when one of these variables was the 
dependent variable. Correlations between the aforementioned inﬂammatory markers were 
analyzed using the Spearman’s correlation coefﬁcient.
All statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS), version 21.0 (IBM Corp., Armonk, NY, USA). Results were considered statistically 
signiﬁcant at a two-sided p-value less than 0.05. Figures were constructed using GraphPad 
Prism 5.01 for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
Of the 905 patients enrolled in the chart review study, 862 had available data on the 
total WBC counts whereas 856 had available data on the CRP level upon admission. In 
90 patients also the differential WBC counts were determined. Eighty-six of them had 
available data on the neutrophil and lymphocyte counts as well as the CRP level within 24 
h after admission and these patients were included in the present pilot study.
Table 1 presents the baseline characteristics of the 86 included patients. The mean age 
was 80.1 ± 6.5 years; 37.2% were male. Thirteen patients were diagnosed with delirium, 
of whom eight had delirium on admission and ﬁve had incident delirium. The median 
number of days between admission and diagnosis of incident delirium was 6 (range: 
3–13). No statistically signiﬁcant differences were found in age, CCI score, and the other 
demographic characteristics between patients with and without delirium.
Analyses of inflammatory markers
Mean levels and corresponding 95% conﬁdence intervals (CIs) of the investigated inﬂam-
matory markers in patients with and without delirium are presented in table 2. In adjusted 
models, mean levels of NLR remained statistically signiﬁcantly higher in patients with 
delirium (9.10, 95% CI: 6.54–12.65) than in those without (5.18, 95% CI: 4.53–5.93; p 
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= 0.003; ﬁgure 1). With regard to the other inﬂammatory markers, mean neutrophil frac-
tions were signiﬁcantly higher in patients with delirium (78.1%, 95% CI: 73.5–82.8) than 
in those without (72.7%, 95% CI: 70.8–74.6; p = 0.037) and mean lymphocyte fractions 
were signiﬁcantly lower in patients with delirium (11.0%, 95% CI: 7.5–14.6) than in those 
without (16.3%, 95% CI: 14.8–17.7; p = 0.008). No differences were found in total WBC 
count, neutrophil and lymphocyte counts, and CRP level between the groups, although the 
lymphocyte count was at the border of signiﬁcance lower in patients with delirium than in 
those without (p = 0.080).
In the total group of patients, NLR showed a weak positive correlation with CRP (r = 
0.389, p < 0.001; ﬁgure 2A), a moderate positive correlation with the total WBC count (r 
= 0.588, p < 0.001; ﬁgure 2B), a strong positive correlation with the neutrophil count (r = 
Table 1. Baseline characteristics of the study participants
Variables No delirium (n = 73) Delirium (n = 13) p-value
Male 28 (38.4) 4 (30.8) 0.759 a
Age (years) 79.9 ± 6.5 81.2 ± 6.6 0.517 b
Place of residence before admission:
 Home (with or without home care) 56 (76.7) 9 (69.2) 0.726 a
 Institutional care facility 17 (23.3) 4 (30.8)
First time on the ward of geriatrics 45 (61.6) 9 (69.2) 0.759 a
Charlson Comorbidity Index 2.0 (1.0–4.0) 4.0 (1.5–5.5) 0.110 c
Notes: Values are expressed as mean ± SD for normally distributed continuous variables, median (in-
terquartile range) for not normally distributed continuous variables and n (percentages) for categorical 
variables. a Fisher’s exact test. b Student’s t-test. c Mann-Whitney U-test.
Table 2. Mean levels of inﬂammatory markers
Variables No delirium (n = 73) Delirium (n = 13) p-value
Total WBC count (×109/l) 9.33 (8.46–10.30) 7.83 (6.17–9.95) 0.186 a,c
Neutrophil count (×109/l) 6.53 (6.25–6.83) 7.04 (6.31–7.85) 0.220 c
Neutrophil fraction (% of WBCs) 72.7 (70.8–74.6) 78.1 (73.5–82.8) 0.037
Lymphocyte count (×109/l) 1.37 (1.24–1.50) 1.06 (0.75–1.38) 0.080
Lymphocyte fraction (% of WBCs) 16.3 (14.8–17.7) 11.0 (7.5–14.6) 0.008
NLR 5.18 (4.53–5.93) 9.10 (6.54–12.65) 0.003 c
CRP (mg/l) 9.7 (6.2–15.3) 26.3 (8.8–78.3) 0.099 b,c
Notes: Values are expressed as mean (95% conﬁdence intervals) and are adjusted for age, sex, Charlson 
Comorbidity Index score, CRP level and total WBC count unless otherwise speciﬁed. a Not adjusted for 
total WBC count. b Not adjusted for CRP level. c Values are presented as the back-transformed natural 
log values.
Abbreviations: CRP, C-reactive protein; NLR, neutrophil-lymphocyte ratio; WBC, white blood cell.
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0.738, p < 0.001; ﬁgure 2C) and a strong negative correlation with the lymphocyte count 
(r = –0.638, p < 0.001; ﬁgure 2D).
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Figure 1. NLR in patients with and without delirium. (A) Unadjusted levels of NLR in patients with and 
without delirium. Lines represent medians, open dots represent patients with delirium on admission, 
gray dots represent patients with incident delirium. (B) Mean levels and corresponding 95% conﬁdence 
intervals of NLR in patients with and without delirium. Values are the back-transformed natural log val-
ues. Model is adjusted for age, sex, the Charlson Comorbidity Index score, C-reactive protein level, and 
white blood cell count.
Abbreviation: NLR, neutrophil-lymphocyte ratio.
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Figure 2. Correlations between the neutrophil-lymphocyte ratio (NLR) and C-reactive protein (CRP) (A), 
white blood cell (WBC) count (B), neutrophil count (C) and lymphocyte count (D). r = Spearman’s cor-
relation coefﬁcient.
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DISCUSSION
In the present pilot study, we found elevated mean levels of NLR in elderly patients with 
delirium.
We are aware that no conclusions on causality can be drawn from this observational 
study; however, our results might suggest that an inadequate response of the immune 
system and oxidative stress might be both involved in the pathophysiology of delirium.
Activation of the immune system is a prominent feature of many conditions associated 
with delirium, such as infections and traumas. Several cytokines and inﬂammatory markers 
have already been detected in serum and cerebrospinal ﬂuid during delirium [21-24]. In 
various stressful situations, the physiological response of the immune system is character-
ized by an increase in neutrophils and a decrease in lymphocytes [25, 26]. Neutrophils play 
an important role in the ﬁrst-line defense during inﬂammation; once activated, they release 
reactive oxygen species, myeloperoxidase and proteolytic enzymes in an attempt to destroy 
pathogens or damaged cells [27, 28].
Disruption of the blood-brain barrier (BBB) and brain damage have previously been sug-
gested as possible underlying mechanisms for delirium [29]. It has been found that, at an 
early stage of systemic inﬂammation, neutrophils adhere to activated endothelial cells of 
the BBB, migrate across the BBB, and release reactive oxygen species and proteases, which 
in turn causes destruction of the endothelial cell alignment [4, 28, 30, 31]. At the same 
time, several other processes also increase the permeability of the BBB [30]. Disruption 
of the BBB will lead to enhanced cytokine transport into the brain. These cytokines may 
activate microglia, which in turn will produce a wide range of inﬂammatory markers and 
reactive oxygen species [32]. Production of reactive oxygen species by neutrophils and 
microglia may lead to oxidative stress and may ultimately result in neuronal damage and 
apoptosis.
Lymphocytes play an important role in the regulation of an appropriate inﬂammatory 
response. Although a decrease in lymphocytes is a normal response during periods of acute 
stress, a chronic decrease in lymphocytes due to increased levels of catecholamine and 
cortisol, redistribution of lymphocytes to lymphatic tissue, and accelerated apoptosis might 
lead to a detrimental inﬂammatory state and ultimately result in poor clinical outcomes 
[25, 33, 34].
NLR is the balance between neutrophils and lymphocytes and integrates two compo-
nents of the immune system in one marker. Since in our study the individual neutrophil and 
lymphocyte counts were not (or not strongly) associated with delirium in comparison to 
NLR, it might be suggested that it is the balance between the two that is out of range and 
not particularly the two individual WBC subtypes. Therefore, an increased NLR might be 
suggestive for a decreased physiological reserve to respond adequately to an inﬂammatory 
insult.
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In various pathological conditions, elevated NLR levels have been found to be an inde-
pendent predictor of disease severity and poor prognosis. Moreover, NLR has been found 
to be a more powerful predictor of adverse outcomes in comparison with conventional 
inﬂammatory markers, such as the total WBC count, the individual WBC subtypes and 
CRP [13-16]. In the present study, we found no differences in mean levels of CRP, WBC, 
neutrophils and lymphocytes between patients with and without delirium. Mean levels of 
NLR showed statistically signiﬁcant increases in patients with delirium, even after adjust-
ment for inﬂammatory markers. These ﬁndings might suggest an independent role of NLR 
in delirium above conventional inﬂammatory markers.
To the best of our knowledge, this is the ﬁrst study investigating a possible association 
between NLR and delirium. A few studies have demonstrated that elevated NLR levels 
are associated with neuropsychiatric disorders such as Alzheimer’s disease [8], Parkinson’s 
disease [35] and schizophrenia [6] as well as with cognitive dysfunction after carotid end-
arterectomy [36]. Limited research has focused on the possible association of neutrophils 
and lymphocytes with delirium. In line with our study, Watts et al. [37] found no difference 
in neutrophil counts between patients with and without delirium who were admitted to an 
intensive care unit. Tanaka [38] found that a decreased lymphocyte count was associated 
with a combined outcome of perioperative delirium and acute exacerbation of behav-
ioral and psychological symptoms of dementia. Zuliani et al. [39] found that a decreased 
lymphocyte count was associated with subsyndromal delirium. On the contrary, Inoue et 
al. [40] did not ﬁnd an association between the lymphocyte count and the number of 
days that intensive care unit patients were free of both delirium and coma. In the present 
study, we found no association between the lymphocyte count and delirium, but the mean 
lymphocyte count seemed to be lower in patients with delirium than in those without. Of 
note, three of the four previous studies [38-40] did not have delirium as a clear outcome, 
which makes it difﬁcult to compare the results.
Limitations and strengths
This study has some limitations. First, as this was a pilot study in a relatively small group 
of patients, the ﬁndings need to be conﬁrmed in a larger study. Moreover, due to the 
small group of patients with delirium, we were not able to perform stratiﬁed analyses 
for ‘‘delirium on admission’’ and ‘‘incident delirium’’. It might be interesting to evaluate 
the diagnostic and predictive power of NLR in future studies. Second, the observational 
design with a single measurement of NLR limits the ability to identify causal associations. 
Repeated NLR measurements over time are required to provide evidence for a possible role 
of NLR in the pathogenesis of delirium. Third, it might be speculated that other comorbidi-
ties, such as cardiovascular diseases [9-11], diabetes [41], malignancies [12], infection [15], 
and inﬂammation [14], might have inﬂuenced the mean levels of NLR; however, even after 
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adjustment for the CCI and other inﬂammatory markers, estimates remained statistically 
signiﬁcant. Fourth, only in a relatively small number of patients neutrophil and lymphocyte 
counts were measured on admission and this might have introduced some selection bias. 
Unfortunately, it is unclear why differential WBC counts were measured in these patients. 
The reason was probably not an increased inﬂammatory state, since the total WBC counts 
and CRP levels were lower in these patients than in the patients not included in this pilot 
study (data not shown).
An important strength is the use of an easily applicable marker, which combines infor-
mation of several components of the immune system, as it has been suggested that the 
pathophysiology of delirium is multifactorial.
CONCLUSION
In this pilot study in older, acutely ill hospitalized patients, we found that patients with de-
lirium had higher levels of NLR than patients without delirium. This ﬁnding might suggest 
that an inadequate response of the immune system and oxidative stress may play a role 
in the pathogenesis of delirium. Larger studies with repeated measurements of NLR over 
time are needed to conﬁrm the possible role of NLR in the pathogenesis of delirium and 
to investigate whether NLR can be used as a diagnostic and predictive marker for delirium.
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ABSTRACT
Background/Aim
Delirium is a major problem in older hospitalized patients whereas the pathophysiology 
is poorly understood. Increasing evidence suggests that different pathways may play a 
role in the pathophysiology depending on the etiological factors of the delirium and the 
population studied. The aim of the present study was to investigate potential differences 
in mean plasma levels of neopterin, amino acids, amino acid ratios and homovanillic acid 
between two groups of patients with delirium, i.e. acutely ill medical patients and patients 
with a delirium after elective cardiac surgery.
Methods
Data from two studies, including acutely ill medical patients aged 65 years and older (the 
DITO study), and patients aged 70 years and older undergoing elective cardiac surgery 
(the DECO study), were used. Differences in biomarker levels between these two groups 
were investigated using univariate analysis of variance with adjustments for age, sex, 
comorbidities, C-reactive protein (CRP) and the estimated glomerular ﬁltration rate (eGFR), 
where appropriate. Linear regression analysis was used to identify potential determinants 
of biochemical markers in the two groups.
Results
Eighty patients with delirium were included (23 acutely ill medical patients and 57 elective 
cardiosurgical patients). After adjustment, higher mean neopterin levels (93.1 vs. 47.3 
nmol/l, p = 0.001) and higher phenylalanine/tyrosine ratios (1.39 vs. 1.15, p = 0.032) were 
found in acutely ill medical patients compared to elective cardiosurgical patients. Multiple 
linear regression analysis showed that CRP was positively correlated with neopterin in 
acutely ill medical patients, explaining 28.4% of the variance in neopterin, whereas eGFR 
was negatively correlated with neopterin in elective cardiosurgical patients, explaining 
53.7% of the variance in neopterin.
Conclusion
In this study, we found differences in mean neopterin levels and phenylalanine/tyrosine 
ratios between acutely ill medical and elective cardiosurgical patients with delirium. More-
over, differences in determinants of neopterin were found between the two groups. Our 
ﬁndings suggest that, in acutely ill medical patients, neopterin levels are mainly determined 
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by inﬂammation/oxidative stress whereas in elective cardiosurgical patients, neopterin 
levels are mainly driven by renal function/ﬂuid status. These ﬁndings suggest that the 
markers and pathways that might be involved in the pathophysiology of delirium may 
differ between speciﬁc groups of patients with delirium.
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INTRODUCTION
Delirium – an acute neuropsychiatric syndrome characterized by disturbances in attention, 
awareness and cognition – is a common and severe disorder in elderly patients [1-3]. It is 
associated with poor clinical outcomes including prolonged hospital stay, loss of indepen-
dence, increased risk of cognitive decline and mortality [4]. Although it is widely accepted 
that the cause of delirium is multifactorial with a complex interplay between predisposing 
factors (e.g. advanced age and dementia) and precipitating factors (e.g. acute medical 
illness and surgery), the pathophysiology of delirium is still poorly understood [3].
Increasing evidence suggests that delirium might have different pathophysiological 
mechanisms depending on the precipitating factor and the health status of the patient 
(acutely ill or relatively healthy) [5, 6]. Several mechanisms may play a role and include, 
among others, activation of the immune system, oxidative stress and disturbances in 
serotonergic and dopaminergic neurotransmission [7]. During immune system activation, 
monocytes and macrophages are stimulated to produce neopterin [8]. The association 
between this novel potential biomarker, neopterin, and delirium has been investigated in 
three previous studies which included acutely ill medical patients [9], patients undergo-
ing elective cardiac surgery [10] and acute hip fracture patients undergoing surgery [11]. 
In all three studies, neopterin levels were increased in patients with delirium compared 
to patients without delirium. However, when comparing the results of the studies, large 
differences are observed in mean neopterin levels between the different patient groups. 
Considerably lower mean neopterin levels were found in surgical patients with delirium 
[10, 11] than in acutely ill medical patients with delirium [9]. Also interestingly, neopterin 
levels measured in patients with a delirium after cardiac surgery [10] were in the same 
order as neopterin levels measured in acutely ill medical patients without delirium [9]. 
These observations might suggest differences in biochemical proﬁles and pathophysi-
ological pathways between patient groups with delirium. Adequate knowledge regarding 
possible differences in the pathophysiology is required to improve delirium prevention and 
treatment.
The aim of this study was to investigate potential differences in mean plasma levels 
of several biochemical parameters, i.e. neopterin, amino acids, amino acid ratios and 
dopamine’s metabolite homovanillic acid (HVA), between acutely ill medical patients with 
delirium and patients who developed a delirium after elective cardiac surgery.
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METHODS
Study populations
In this study, we used data from the Delirium In The Old (DITO) study [9, 12] and the 
DElirium pathogenesis, Cognition and Outcome (DECO) study [10]. Only patients with 
delirium were included in the present study. The most relevant procedures of the two 
studies will be described here; detailed information can be found in previous publications 
[9, 10, 12].
The DITO study was a cross-sectional study in patients aged 65 years and older who 
were acutely admitted to the wards of Internal Medicine and Geriatrics of the Erasmus 
University Medical Center (Erasmus MC) and the ward of Geriatrics of the Harbor Hospital, 
Rotterdam, the Netherlands. Exclusion criteria were a diagnosis of Lewy body dementia, 
Parkinson’s disease, neuroleptic malignant syndrome, tardive dyskinesia, ongoing treat-
ment with antipsychotics or other psychiatric medications except haloperidol and benzo-
diazepines, aphasia, insufﬁcient understanding of the Dutch language and a Mini-Mental 
State Examination (MMSE) score < 10 points out of 30.
The DECO study was a prospective cohort study in patients aged 70 years and older who 
underwent elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, or 
both) at the department of Cardiothoracic Surgery of the Erasmus MC. Exclusion criteria 
were surgery in which deep cooling, circulatory arrest or an emergency procedure was 
required, insufﬁcient understanding of the Dutch language, preoperative delirium and 
insufﬁcient adherence to the protocol.
In both studies, written informed consent was obtained from all participants or their 
representatives. The study protocols were approved by the Medical Ethics Committee of 
the Erasmus MC.
Procedures
In both studies, participants were assessed daily for the presence of delirium by the nursing 
and medical staff and by members of the research teams until discharge or until 7 days 
after surgery.
In the DITO study, the 13-items Delirium Observation Screening scale was used to screen 
for a change in behavior [13]. The diagnosis of delirium was made by a geriatrician, accord-
ing to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV) [1], and was based on psychiatric examination of the patient, the medical and 
nursing records, the Delirium Observation Screening scale scores and information given by 
the patient’s closest relative. Cognitive functioning was assessed in absence of a delirium 
using the MMSE [14].
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In the DECO study, the diagnosis of delirium was made by a senior psychiatrist and/or a 
trained researcher in daily assessments between 10.00 and 12.00 h using the Confusion 
Assessment Method for the Intensive Care Unit (which follows the criteria for delirium of 
the DSM-IV) [15] and was based on psychiatric examination of the patient and information 
in the medical and nursing records. Delirium lasting more than 1 day was considered 
clinically relevant. The ﬁrst day after surgery was not taken into account because of pos-
sible residual effects of anesthesia. On the day before surgery, cognitive functioning was 
assessed using the MMSE.
In the DITO study, blood samples were collected within 48 h after admission. When a 
patient developed delirium during the hospital stay, new blood samples were collected 
within 24 h after the onset of delirium and were used instead of the ﬁrst blood samples for 
the statistical analyses. In the DECO study, blood samples were collected on the day before 
surgery and the second day after surgery.
In the present study, we compared the biochemical data collected in the DITO study with 
the postoperative biochemical data from the DECO study.
Biochemical measurements
In both studies, nonfasting blood was collected preferably between 8 and 10 a.m. in an 
8-ml tube containing ethylene diamine tetra-acetic acid. After blood sampling, the tubes 
were protected from light to prevent oxidative loss of neopterin [16], and stored at room 
temperature to prevent changes in the transfer of amino acids between plasma and blood 
cells [17]. Within 3 h, the blood was centrifuged for 20 min at 2,650 g and 20 °C. The 
obtained plasma was stored at –80 °C until analysis.
In both studies, neopterin, amino acids and HVA were determined by the same proce-
dures and by the same analytical staff. Plasma neopterin levels were determined by high-
performance liquid chromatography (HPLC) after acid oxidation [18]. Plasma amino acid 
levels were measured using HPLC with automated pre-column derivatization with ortho-
phthalaldehyde [17] and plasma HVA levels were determined by reversed-phase HPLC and 
electrochemical detection, as previously described for the measurement of serotonin [19].
C-reactive protein (CRP) levels and the estimated glomerular ﬁltration rate (eGFR) were 
taken from the medical records. In case of the DECO study, the 2-days postoperative levels 
were recorded. The eGFR was determined by the following Modiﬁcation of Diet in Renal 
Disease formula: 175 × [serum creatinine (μmol/l) × 0.0113]−1.154 × age−0.203 × 0.742 (if 
female).
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Statistical analysis
Differences in participant characteristics between acutely ill medical and elective cardio-
surgical patients were evaluated using the chi-square test for categorical variables and the 
Mann-Whitney U-test or the Student’s t-test for continuous variables, depending on the 
distribution of the data.
Univariate analysis of variance was used to investigate potential differences in mean 
levels of biochemical parameters (dependent variable) between acutely ill medical and elec-
tive cardiosurgical patients. For this purpose, biochemical parameters with a non-normal 
distribution were logarithmically transformed (neopterin, HVA, all amino acids and amino 
acid ratios). Analyses were adjusted for age, sex and Charlson Comorbidity Index (CCI). The 
model including neopterin was additionally adjusted for CRP and eGFR, since neopterin is 
an inﬂammatory marker which is mainly excreted by the kidneys [8]. In additional analyses, 
neopterin, HVA, all amino acids and amino acid ratios were also adjusted for MMSE score. 
All mean levels and corresponding 95% conﬁdence intervals (CIs) presented in this manu-
script are the back-transformed log10-values.
Unadjusted linear regression analysis was performed to identify potential determinants 
of biochemical parameters which were statistically signiﬁcantly different between the 
groups. Secondly, variables with a p-value d 0.10 were included in a multiple linear regres-
sion analysis, stratiﬁed for study, to determine the relative contribution of each variable to 
the total variance in the biochemical parameter. Semi-partial (part) correlation coefﬁcients 
were squared in order to calculate the percentage of total variance that was explained by 
each variable.
Statistical Package for the Social Sciences, version 21.0 (IBM Corp., Armonk, NY, USA) 
was used to perform the statistical analyses. A two-tailed p < 0.05 was deﬁned as sta-
tistically signiﬁcant. Figures were constructed using GraphPad Prism 5.01 for Windows 
(GraphPad Software, San Diego, CA, USA).
RESULTS
Participant characteristics
Of the 211 patients enrolled in the two studies, 81 were diagnosed with delirium. One 
participant from the DECO study was excluded due to withdrawal of consent. In total, 
23 acutely ill medical patients and 57 elective cardiosurgical patients with delirium were 
included. Table 1 presents the demographic and clinical characteristics of these patients. 
Acutely ill medical patients were older (mean 85.9 vs 76.8 years, p < 0.001), had lower 
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MMSE scores (median 20 vs 27, p < 0.001) and lower CRP levels (median 36.0 vs 100.0 
mg/l, p = 0.013) than elective cardiosurgical patients.
Table 1. Characteristics of the study participants
DITO (n = 23) DECO (n = 57) p-value
Male, n (%) 10 (43.5) 34 (59.6) 0.188 e
Age, years, mean ± SD 85.9 ± 4.0 76.8 ± 3.8 < 0.001 f
MMSE score, median (IQR) a,b 20.0 (18.0–25.0) c 27.0 (24.0–28.0) < 0.001 g
CCI score, median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.550 g
CCI score, n (%)
 0 1 (4.3) 11 (19.3)
 1 8 (34.8) 12 (21.1)
 2 7 (30.4) 15 (26.3)
 t3 7 (30.4) 19 (33.3)
CRP, mg/l, median (IQR) d 36.0 (10.0–103.0) 100.0 (60.0–148.0) b 0.013 g
eGFR, ml/min, mean ± SD d 49.4 ± 25.1 48.9 ± 23.2 0.930 f
Notes: Values are expressed as mean ± SD for normally distributed continuous variables, median (in-
terquartile range) for not normally distributed continuous variables and n (percentages) for categorical 
variables. a range 0 (severe cognitive impairment) to 30 (no cognitive impairment). b DITO: measured 
in the absence of delirium, DECO: measured on the day before surgery. c Four values missing. d DITO: 
measured during delirium (on the day of neopterin sampling), DECO: measured during delirium 2 days 
after cardiac surgery. e Chi-square test. f Student’s t-test. g Mann-Whitney U-test.
Abbreviations: CCI, Charlson Comorbidity Index; CRP, C-reactive protein; eGFR, estimated glomerular 
ﬁltration rate; IQR, interquartile range; MMSE, Mini-Mental State Examination; SD, standard deviation.
Analyses of biochemical parameters
The mean levels and corresponding 95% CIs of the investigated biochemical parameters 
in acutely ill medical and elective cardiosurgical patients are presented in tables 2 and 
3. After adjustment for age, sex, CCI, eGFR and CRP levels, mean neopterin levels were 
signiﬁcantly higher in acutely ill medical patients (93.1 nmol/l, 95% CI: 69.3–125.3) than in 
elective cardiosurgical patients (47.3 nmol/l, 95% CI: 40.1–55.8) (p = 0.001). Furthermore, 
mean phenylalanine/tyrosine (Phe/Tyr) ratios were signiﬁcantly higher in acutely ill medical 
patients (1.39, 95% CI: 1.22–1.58) than in elective cardiosurgical patients (1.15, 95% 
CI: 1.07–1.24) (p = 0.032). No statistically signiﬁcant differences were found in the mean 
levels of the other biochemical parameters. Estimates remained unchanged after additional 
adjustment for MMSE scores (tables S1 and S2, supplementary material).
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Determinants of neopterin
Unadjusted linear regression analysis revealed that neopterin levels were positively corre-
lated with CRP levels in acutely ill medical patients, and negatively correlated with eGFR in 
elective cardiosurgical patients (table 4, ﬁgure 1). Trends towards lower neopterin levels 
Table 2. Mean levels of biochemical parameters
DITO (n = 23) DECO (n = 57) p-value
Neopterin, nmol/l 93.1 (69.3–125.3) 47.3 (40.1–55.8) 0.001 a
Homovanillic acid, nmol/l 120.2 (79.6–181.1) b 160.3 (128.5–199.5) b 0.279
Glutamic acid, μmol/l 46.7 (37.3–58.3) 35.4 (31.3–39.9) 0.059
Serine, μmol/l 80.2 (68.4–94.0) 75.5 (69.2–82.2) 0.555
Glycine, μmol/l 182.0 (157.0–210.9) 198.2 (182.8–214.3) 0.375
Citrulline, μmol/l 24.0 (19.3–29.8) 23.1 (20.6–26.0) 0.803
Arginine, μmol/l 35.4 (28.1–44.6) 44.0 (38.7–49.9) 0.152
Taurine, μmol/l 35.7 (27.2–47.1) 33.6 (28.9–38.9) 0.722
Tyrosine, μmol/l 56.6 (47.2–67.9) 66.2 (60.0–73.1) 0.189
Valine, μmol/l 208.4 (182.8–237.7) 202.8 (188.8–217.8) 0.758
Methionine, μmol/l 22.4 (18.4–27.3) 28.5 (25.6–31.8) 0.063
Tryptophan, μmol/l c 30.4 (23.5–37.2) 33.8 (30.1–37.5) 0.440
Phenylalanine, μmol/l 78.5 (70.0–88.3) 76.0 (71.4–81.1) 0.665
Isoleucine, μmol/l 55.8 (47.6–65.5) 67.6 (61.9–73.6) 0.069
Leucine, μmol/l 121.9 (104.5–142.2) 123.9 (113.8–134.6) 0.875
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 
values unless otherwise speciﬁed. Models are adjusted for age, sex and Charlson Comorbidity Index. 
The model including neopterin is adjusted for age, sex, Charlson Comorbidity Index, the estimated 
glomerular ﬁltration rate and C-reactive protein (CRP). a Analysis was performed for 76 patients with 
delirium (DITO n = 23 and DECO n = 53) due to missing CRP levels. b One value missing. c Values were 
not logarithmically transformed.
Table 3. Mean levels of amino acid ratios
DITO (n = 23) DECO (n = 57) p-value
Phenylalanine / tyrosine ratio 1.39 (1.22–1.58) 1.15 (1.07–1.24) 0.032
Tryptophan / LNAAs ratio x 100 a 5.35 (4.37–6.32) 6.11 (5.59–6.64) 0.228
Tyrosine / LNAAs ratio x 100 11.4 (9.8–13.2) 13.1 (12.1–14.2) 0.152
Phenylalanine / LNAAs ratio x 100 16.5 (14.6–18.6) 15.3 (14.4–16.4) 0.363
Citrulline / arginine ratio 0.68 (0.52–0.89) 0.53 (0.45–0.61) 0.153
Taurine / (serine x methionine) ratio x 100 1.99 (1.42–2.79) 1.56 (1.30–1.87) 0.273
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 
values unless otherwise speciﬁed. Models are adjusted for age, sex and Charlson Comorbidity Index. a 
Values were not logarithmically transformed.
Abbreviations: LNAAs, large neutral amino acids (tryptophan, phenylalanine, tyrosine, valine, isoleu-
cine and leucine).
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Figure 1. Unadjusted linear regression analyses between neopterin and age (A), CRP (B) eGFR (C) and 
MMSE score (D) in acutely ill medical patients with delirium (DITO) and patients with delirium after elec-
tive cardiac surgery (DECO).
Abbreviations: CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; MMSE, Mini-Mental 
State Examination.
73
Differences in mean neopterin levels between two specific groups of patients with delirium
2
were found for increasing age (p = 0.060) and increasing eGFR (p = 0.061) in acutely ill 
medical patients. No correlation was found between neopterin, CCI and MMSE scores in 
both groups of patients (p > 0.10).
Table 4. Unadjusted linear regression analyses of potential determinants of neopterin and Phe/Tyr ratio
Variable
Log10 (neopterin (nmol/l)) – DITO Log10 (neopterin (nmol/l)) – DECO
B 95% CI p-value R² B 95% CI p-value R²
Age −0.032 (−0.064; 0.001) 0.060 0.159  0.006 (−0.015; 0.026) 0.583 0.006
Sex −0.085 (−0.370; 0.199) 0.539 0.018 −0.018 (−0.176; 0.139) 0.816 0.001
CCI  0.039 (−0.043; 0.122) 0.332 0.045  0.022 (−0.024; 0.069) 0.339 0.017
CRP  0.002 (0.001; 0.004) 0.002 0.364  0.001 (0.000; 0.002) 0.221 0.029
eGFR −0.005 (−0.010; 0.000) 0.061 0.157 −0.009 (−0.011; −0.007) < 0.001 0.537
MMSE  0.001 (−0.031; 0.034) 0.940 0.000 0.004 (−0.023; 0.031) 0.756 0.002
Variable
Log10 (Phe/Tyr ratio) – DITO Log10 (Phe/Tyr ratio) – DECO
B 95% CI p-value R² B 95% CI p-value R²
Age −0.006 (−0.021; 0.009) 0.436 0.029 −0.001 (−0.007; 0.005) 0.765 0.002
Sex  0.049 (−0.072; 0.170) 0.411 0.032 −0.010 (−0.056; 0.035) 0.647 0.004
CCI  0.023 (−0.012; 0.057) 0.189 0.081  0.003 (−0.011; 0.016) 0.705 0.003
MMSE  0.000 (−0.008; 0.008) 0.988 0.000  0.000 (−0.014; 0.014) 0.966 0.000
Notes: Age was measured in years, sex was coded as 1 = male, 2 = female, CCI was measured in points, 
CRP was measured in mg/l, eGFR was measured in ml/min and MMSE was measured in points. B = re-
gression coefﬁcient; R² = squared correlation coefﬁcient.
Abbreviations: CI, conﬁdence interval; CCI, Charlson Comorbidity Index; CRP, C-reactive protein; eGFR, 
estimated glomerular ﬁltration rate; MMSE, Mini-Mental State Examination; Phe, phenylalanine; Tyr, 
tyrosine.
Multiple linear regression analysis revealed that a model based on age, CRP and eGFR 
could explain 53.2% of the variance in neopterin in acutely ill medical patients (table 5). 
In this model, CRP levels remained positively correlated with neopterin levels and explained 
28.4% of the variance in neopterin. Age and eGFR explained 8.53% and 3.96% of the 
variance in neopterin respectively, but remained not statistically signiﬁcant determinants 
of neopterin. In elective cardiosurgical patients, the same model explained 56.7% of the 
variance in neopterin (table 5). In this model, eGFR remained negatively correlated with 
neopterin levels and explained 53.7% of the variance in neopterin. Age and CRP explained 
0.18% and 2.76% of the variance in neopterin respectively and remained not statistically 
signiﬁcant determinants of neopterin.
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Determinants of Phe/Tyr ratio
Unadjusted linear regression analysis revealed that age, sex, CCI and MMSE scores were 
not statistically signiﬁcantly correlated with Phe/Tyr ratios in both acutely ill medical and 
elective cardiosurgical patients (table 4). Also no trends towards correlation were found.
DISCUSSION
In this study, we found higher mean levels of neopterin and higher Phe/Tyr ratios in acutely 
ill medical patients with delirium than in patients who developed a delirium after elective 
cardiac surgery. These ﬁndings suggest that the markers and pathways that might be 
involved in the pathophysiology of delirium in acutely ill medical patients may differ from 
those in elective cardiosurgical patients.
Delirium frequently occurs in conditions in which the immune system is activated, 
and this suggests that inﬂammatory mediators may play a role in the pathophysiology. 
Several cytokines and inﬂammatory markers have already been found to be increased in 
acutely ill medical [9, 20] and cardiosurgical patients [21] with delirium. Neopterin can be 
considered as a marker of cell-mediated immune system activation and oxidative stress 
as it is primarily produced by activated monocytes and macrophages upon stimulation 
with the pro-inﬂammatory cytokine interferon-gamma (IFN-γ). Previous studies have found 
increased neopterin levels in both medical and surgical patients with delirium [9-11], and 
this suggests a potential role for neopterin in the pathophysiology of delirium. Neverthe-
less, in the present study we found a large difference in mean neopterin levels between 
acutely ill medical and elective cardiosurgical patients with delirium, whereas all neopterin 
measurements were performed in the same laboratory using identical procedures. This 
ﬁnding remained signiﬁcant after adjustment for potential confounders.
Substantial differences in determinants of neopterin levels were found between the 
two populations. CRP levels were the strongest determinant of neopterin levels in acutely 
ill medical patients, explaining 28.4% of the variance in neopterin, whereas the eGFR 
was the strongest determinant of neopterin, explaining 53.7% of the variance in neop-
terin, in elective cardiosurgical patients. These ﬁndings suggest that, in acutely ill medical 
patients, neopterin levels are potentially mainly determined by inﬂammation/oxidative 
stress, whereas in elective cardiosurgical patients, neopterin levels are mainly driven by 
renal function/ﬂuid status. In both populations, the model based on age, CRP and eGFR 
explained approximately half of the variance in neopterin and therefore the remaining 
variance might be determined by other factors, e.g. the presence of comorbid cognitive 
disorders, other medical conditions [8] or the use of speciﬁc drugs, such as acetylsalicylic 
acid [22] and statins [23]. Several studies have shown that a decrease in cognitive perfor-
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mance is accompanied by an increase in neopterin levels [24, 25]. In the present study, we 
found that acutely ill medical patients had signiﬁcantly lower MMSE scores than patients 
who developed a delirium after elective cardiac surgery. This shows that acutely ill medical 
patients were cognitively more impaired than the elective cardiosurgical patients. However, 
the estimates did not change after additional adjustment for MMSE scores and therefore, 
we can not conﬁrm that the difference in mean neopterin levels is caused by a difference 
in cognitive performance between the two groups.
In the present study, we found no correlation between CRP and neopterin levels in 
elective cardiosurgical patients, although CRP levels were signiﬁcantly higher in elective 
cardiosurgical patients than in acutely ill medical patients. A previous study, performed in 
patients who underwent CABG, showed that both CRP and neopterin levels increased after 
on-pump CABG, but the increase was signiﬁcantly greater for CRP than for neopterin [26]. 
This ﬁnding suggests a poor correlation between CRP and neopterin after on-pump CABG, 
which is in line with our ﬁndings. Since CRP is produced by other cells than neopterin, it 
might be possible that CRP levels reﬂect the activity of several other components of the 
immune system in elective cardiosurgical patients than in acutely ill medical patients.
Tetrahydrobiopterin (BH4) functions as an essential cofactor in several enzymatic reac-
tions involved in the production of serotonin and dopamine [27], two neurotransmitters 
that may play a role in delirium [7]. The Phe/Tyr ratio is an indirect measure of the BH4 
status, as it reﬂects the activity of the enzyme phenylalanine hydroxylase, an enzyme that 
uses BH4 as an essential cofactor [18, 27]. An elevated ratio of phenylalanine to tyrosine 
might suggest a decreased BH4 availability. In previous delirium studies, controversial results 
have been reported. In acutely ill medical patients, an increased Phe/Tyr ratio was found 
in patients with delirium compared to patients without delirium [12], whereas in patients 
who underwent cardiac surgery, no differences in BH4 levels and Phe/Tyr ratios were found 
between patients with and without delirium [10]. In the present study, we found higher 
Phe/Tyr ratios in acutely ill medical patients with delirium than in patients who developed 
a delirium after elective cardiac surgery. This ﬁnding might suggest a decreased availability 
of the essential cofactor BH4 in the production of serotonin and dopamine in acutely ill 
medical patients with delirium. No determinants of the Phe/Tyr ratio could be identiﬁed.
Limitations and strengths
This study has some limitations. First, the two studies used in the present study were 
not developed to compare these with each other. In- and exclusion criteria were differ-
ent and this might have inﬂuenced the results. Although we have adjusted our analyses 
for several covariates, we cannot exclude residual confounding. Second, we used CRP as 
indirect marker of inﬂammation in analyses performed to identify possible determinants 
of neopterin. However, CRP is an acute phase reactant and might be a poor marker of 
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cell-mediated immune system activation. Therefore, it might be possible that cell-mediated 
immune system activation and oxidative stress have played a larger role in both patient 
groups. Adjustment for inﬂammation markers other than CRP (e.g. IFN-γ) would probably 
have given more insights into the results. Third, our ﬁndings were obtained in a relatively 
small group of patients; therefore, the ﬁndings need to be conﬁrmed in a larger study.
The present study has several strengths. First, the investigated markers were determined 
in the same laboratory using identical procedures; therefore, potential differences in mean 
levels of the investigated markers due to differences in the assay are unlikely. Second, in 
the two studies, patients were intensively monitored for clinical symptoms of delirium and 
the diagnosis of delirium was made by a geriatrician or psychiatrist using DSM-IV criteria. 
This makes it less likely that delirium was missed or that symptoms were misdiagnosed.
CONCLUSION
In this study, we found that acutely ill medical patients with delirium had higher levels of 
neopterin and higher Phe/Tyr ratios than patients who developed a delirium after elec-
tive cardiac surgery. Differences in determinants of neopterin were found between the 
two groups. Our ﬁndings suggest that, in acutely ill medical patients, neopterin levels are 
mainly determined by inﬂammation/oxidative stress whereas in elective cardiosurgical pa-
tients, neopterin levels are mainly driven by renal function/ﬂuid status. These ﬁndings could 
suggest that the markers and pathways that might be involved in the pathophysiology 
of delirium in acutely ill medical patients may differ from those in elective cardiosurgical 
patients.
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SUPPLEMENTARY MATERIAL
Table S1. Mean levels of biochemical parameters after additional adjustment for MMSE score
DITO (n = 19) a DECO (n = 57) p-value
Neopterin, nmol/l 97.9 (68.4–140.3) 47.3 (39.9–56.0) 0.002 b
Homovanillic acid, nmol/l 111.2 (65.9–187.9) c 162.6 (129.1–204.6) c 0.252
Glutamic acid, μmol/l 42.2 (31.9–55.8) 36.7 (32.4–41.7) 0.436
Serine, μmol/l 76.6 (63.0–93.3) 76.6 (70.0–83.8) 0.994
Glycine, μmol/l 179.1 (149.6–214.3) 198.2 (182.8–214.8) 0.376
Citrulline, μmol/l 20.7 (15.9–26.9) 24.2 (21.5–27.2) 0.349
Arginine, μmol/l 35.1 (26.2–47.0) 44.5 (38.9–50.8) 0.204
Taurine, μmol/l 33.7 (23.8–47.8) 33.6 (29.2–40.1) 0.946
Tyrosine, μmol/l 54.3 (43.8–67.5) 67.0 (60.7–74.0) 0.130
Valine, μmol/l 205.6 (174.2–242.1) 204.2 (189.2–219.8) 0.950
Methionine, μmol/l 21.7 (17.1–27.6) 28.4 (25.5–31.7) 0.079
Tryptophan, μmol/l d 32.0 (23.4–40.7) 33.5 (29.6–37.4) 0.787
Phenylalanine, μmol/l 78.0 (67.9–89.3) 76.6 (71.9–81.5) 0.837
Isoleucine, μmol/l 56.9 (46.5–69.5) 67.5 (61.5–74.0) 0.183
Leucine, μmol/l 121.1 (99.8–147.2) 124.7 (114.3–136.1) 0.816
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 val-
ues unless otherwise speciﬁed. Models are adjusted for age, sex, Charlson Comorbidity Index and MMSE 
score. The model including neopterin is adjusted for age, sex, Charlson Comorbidity Index, the estimated 
glomerular ﬁltration rate, C-reactive protein (CRP) and MMSE score. a Analyses were performed for 19 
patients instead of 23 patients due to missing MMSE scores. b Analysis was performed for 72 patients 
with delirium (DITO n = 19 and DECO n = 53) due to missing CRP levels. c One value missing. d Values 
were not logarithmically transformed.
Abbreviation: MMSE, Mini-Mental State Examination.
Table S2. Mean levels of amino acid ratios after additional adjustment for MMSE score
DITO (n = 19) DECO (n = 57) p-value
Phenylalanine / tyrosine ratio 1.44 (1.21–1.69) 1.14 (1.06–1.23) 0.035
Tryptophan / LNAAs ratio x 100 a 5.63 (4.40–6.86) 6.06 (5.51–6.62) 0.576
Tyrosine / LNAAs ratio x 100 10.9 (9.2–13.1) 13.2 (12.2–14.3) 0.104
Phenylalanine / LNAAs ratio x 100 16.5 (14.3–19.1) 15.3 (14.4–16.4) 0.438
Citrulline / arginine ratio 0.59 (0.43–0.82) 0.54 (0.47–0.63) 0.684
Taurine / (serine x methionine) ratio x 100 2.02 (1.32–3.10) 1.57 (1.30–1.91) 0.352
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 
values unless otherwise speciﬁed. Models are adjusted for age, sex, Charlson Comorbidity Index and 
MMSE score. a Values were not logarithmically transformed.
Abbreviations: LNAAs, large neutral amino acids (tryptophan, phenylalanine, tyrosine, valine, isoleu-
cine and leucine); MMSE, Mini-Mental State Examination.
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ABSTRACT
In an in vitro study, it was found that aspirin might decrease neopterin production and 
tryptophan degradation. The aim of the present study was to evaluate the possible as-
sociation between aspirin use and mean neopterin and tryptophan levels in patients with 
and without a delirium and whether the use of aspirin is associated with a decreased 
prevalence of delirium. Neopterin and tryptophan levels were determined previously in 
acutely ill admitted patients aged t 65 years. The possible inﬂuence of aspirin on mean 
levels of neopterin and tryptophan was investigated with univariate analysis of variance 
in adjusted models. Eighty patients were included; 22 had a delirium. In patients without 
a delirium (no aspirin (n = 31) versus aspirin (n = 27)), mean neopterin levels were 47.0 
nmol/l versus 43.6 nmol/l (p = 0.645) and tryptophan levels were 33.1 μmol/l versus 33.9 
μmol/l (p = 0.816). In patients with a delirium (no aspirin (n = 13) versus aspirin (n = 9)), 
mean neopterin levels were 77.8 nmol/l versus 71.1 nmol/l (p = 0.779) and tryptophan 
levels were 22.4 μmol/l versus 27.3 μmol/l (p = 0.439). No difference was found in the 
distribution of aspirin users between patients with and without a delirium. In this study, 
we found that the use of aspirin had no signiﬁcant effect on mean levels of neopterin and 
tryptophan. However, the raw data suggest that there might be a potential inﬂuence in 
patients with a delirium. Aspirin use was not associated with a decreased prevalence of 
delirium.
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INTRODUCTION
Delirium, an acute neuropsychiatric syndrome, is a common, severe complication in the 
elderly and is associated with poor clinical outcomes including increased morbidity and 
mortality, prolonged hospital stay, loss of independence, and increased rates of cognitive 
decline [1, 2]. The pathophysiological mechanisms underlying delirium are still poorly un-
derstood, but it is widely accepted that delirium occurs due to a complex interplay among 
several biochemical pathways. Therefore, it might be required to interrupt in multiple bio-
chemical pathways at the same time to prevent, treat, or to lower the severity of a delirium.
Activation of the immune system, oxidative stress, and disturbances in the serotonergic 
neurotransmission may all contribute to the development of a delirium. Recently, we 
found that acutely ill hospitalized elderly patients with a delirium have increased levels of 
neopterin [3]. Neopterin is produced primarily by activated monocytes and macrophages in 
response to the pro-inﬂammatory cytokine interferon-gamma (IFN-γ) and its levels reﬂect 
the amount of cell-mediated immune activation and oxidative stress [4, 5]. Furthermore, 
we have found that patients with a delirium have a decreased availability of tryptophan to 
the central nervous system. This decreased availability might result in a decreased serotonin 
production in the brain, since tryptophan is the precursor of serotonin [6].
A study of Schroecksnadel et al. showed that treatment of stimulated peripheral blood 
mononuclear cells with aspirin signiﬁcantly decreased neopterin production and trypto-
phan degradation in vitro [7]. Therefore, the aim of the present study was to evaluate the 
possible association between aspirin use and mean levels of neopterin and tryptophan 
in patients with and without a delirium and additionally, whether the use of aspirin is 
associated with a decreased prevalence of delirium.
METHODS
Participants
The present study was performed within the Delirium In The Old (DITO) study in which 
mean plasma/serum levels of several biochemical parameters, including neopterin and tryp-
tophan, were compared between patients with and without a delirium [3, 6]. In the DITO 
study, a cross-sectional study, we included patients who were admitted to the wards of 
Internal Medicine and Geriatrics of the Erasmus University Medical Center and the ward of 
Geriatrics of the Harbor Hospital, Rotterdam, the Netherlands. All acutely admitted patients 
aged t 65 years were eligible to participate. Exclusion criteria were a diagnosis of Lewy 
Body dementia, Parkinson’s disease, neuroleptic malignant syndrome, tardive dyskinesia, 
ongoing treatment with antipsychotics or other psychiatric medications, except haloperidol 
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and benzodiazepines, aphasia, insufﬁcient understanding of the Dutch language, and a 
Mini-Mental State Examination (MMSE) score < 10 points out of 30. Patients with a MMSE 
< 10 were not included because it can be quite difﬁcult to distinguish between features 
of severe dementia and delirium at admission, as well as to measure improvement of 
cognitive function in this group. Additional exclusion criteria for the present study were 
unclear data regarding the use of non-steroidal anti-inﬂammatory drugs (NSAIDs) in the 
days preceding hospital admission as well as the use of aspirin concomitantly with other 
NSAIDs (as it might be possible that other NSAIDs interfere with aspirin’s potential effect 
on neopterin and tryptophan levels).
Written informed consent was obtained from all participants. In case of a delirium or 
cognitive impairment at the time of admission, informed consent was obtained from a 
representative of the patient. The Medical Ethics Committee of the Erasmus University 
Medical Center approved the study protocol.
Procedures
All participants were observed daily by the nursing and medical staff and by members 
of the research team until discharge. To screen for a change in behavior, the 13-item 
Delirium Observation Screening scale was used during the ﬁrst ﬁve days of admission [8]. 
The diagnosis of delirium was made by a geriatrician, according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [9], and was based on the 
psychiatric examination of the patient, the medical and nursing records, including the 
Delirium Observation Screening scale scores, and information given by the patient’s closest 
relative. When the diagnosis of delirium was doubtful, the case was discussed with the 
geriatric consultation team to gain consensus.
Demographic and clinical data were collected at admission. Age and sex were docu-
mented. Cognitive functioning was assessed in absence of a delirium using the MMSE 
[10]. When it was impossible to score the MMSE during admission because the patient was 
too ill, the cognitive functioning was discussed with a clinician or assessed with informa-
tion from the available medical records. When the clinical opinion was that the patient 
would have a MMSE score t 10, the patient was not excluded from the study. Severity of 
comorbidities was scored using the Charlson Comorbidity Index. This index encompasses 
19 medical conditions and each condition is weighted with a score of 1 to 6 by severity 
[11]. The physical functionality was assessed using the six-item Katz Activities of Daily Liv-
ing (ADL) scale and the Barthel Index [12, 13]. The instrumental functionality was assessed 
using the 7-items Older Americans Resource Scale for Instrumental ADL (OARS-IADL) [12]. 
Frailty was measured with the Identiﬁcation of Seniors at Risk (ISAR) questionnaire [14]. For 
all participants the medication at hospital admission was reviewed for the use of NSAIDs 
(including low dose acetylsalicylic acid and the equivalent drug carbasalate calcium), beta-
89
Potential influence of aspirin on neopterin and tryptophan levels
3
blockers, diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor 
antagonists, calcium channel blockers, nitrates, statins, and dipyridamole.
Blood samples of all patients were collected within 48 h after admission. When a patient 
developed a delirium during the hospital stay, new blood samples were collected within 
24 h after the onset of the delirium and were used, instead of the ﬁrst blood samples, for 
the statistical analyses.
Biochemical measurements
Nonfasting blood was collected preferably between 8 and 10 a.m. in an 8-mL tube con-
taining ethylene diamine tetra-acetic acid. After blood sampling, the tubes were protected 
from light to prevent oxidative loss of neopterin [15], and stored at room temperature 
to prevent changes in the transfer of amino acids between plasma and blood cells [16]. 
Within 3 h, the blood was centrifuged for 20 min at 2,650 g and 20 °C. The obtained 
plasma was stored at –80 °C until analysis.
Plasma neopterin levels were determined by high-performance liquid chromatography 
after acid oxidation, as previously described [17]. Tryptophan levels were determined by 
high-performance liquid chromatography with automated pre-column derivatization with 
ortho-phthalaldehyde [16].
Statistical analyses
Depending on the distribution of the data, differences in demographic and clinical baseline 
characteristics between patients with and without a delirium were evaluated using the 
chi-square test or the Fisher’s exact test for categorical variables and the Mann–Whitney 
U-test or the Student’s t-test for continuous variables.
Levels of neopterin and tryptophan were not normally distributed and were, there-
fore, logarithmically transformed. Univariate one-way analysis of variance was used to 
investigate the association between mean levels of neopterin and tryptophan (dependent 
variable) and the use of aspirin in both patients with and without a delirium. For this 
purpose, analyses were stratiﬁed for aspirin use. Age, sex, Charlson Comorbidity Index 
and statin use were used as covariates. The Charlson Comorbidity Index was added since 
neopterin levels are found to be increased and tryptophan levels decreased in several medi-
cal conditions. Statin use was added since statins might also inhibit neopterin production 
and tryptophan degradation [18]. The model including neopterin was additionally adjusted 
for eGFR, since neopterin is excreted mainly by the kidneys [5]. All mean levels and 95% 
conﬁdence intervals (CI) of neopterin and tryptophan presented in this manuscript are the 
back-transformed log-values. A two-tailed p < 0.05 was deﬁned as statistically signiﬁcant. 
All statistical analyses were performed using the Statistical Package for the Social Sciences 
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(SPSS), version 21.0 (IBM Corp., Armonk, NY, USA). GraphPad Prism 5.01 for Windows 
(GraphPad Software, San Diego, CA, USA) was used to draw the graphs.
RESULTS
Participant characteristics
Of the 86 patients enrolled in the DITO study, 80 were included in the stratiﬁed analyses to 
examine the effect of aspirin use on neopterin and tryptophan levels. Three patients were 
excluded due to unclear data regarding the use of NSAIDs in the days preceding hospital 
admission, 1 patient used diclofenac and 2 patients used carbasalate calcium concomi-
tantly with another NSAID (diclofenac and etoricoxib respectively). Table 1 represents the 
baseline characteristics of the included patients. Twenty-two patients were diagnosed with 
a delirium, of which 21 were admitted to the hospital with a delirium and 1 developed 
a delirium during admission. No difference was found in the number of aspirin users be-
tween patients with and without a delirium (46.6% versus 40.9%, p = 0.651, respectively).
Analysis of biochemical parameters
Mean levels and corresponding 95% CI of neopterin and tryptophan in patients with and 
without a delirium, stratiﬁed for the use of aspirin, are presented in tables 2 and 3.
In the group without a delirium, no signiﬁcant difference was found in the adjusted mean 
levels of neopterin between patients who used aspirin (43.6 nmol/l, 95% CI: 34.5–55.0) 
and patients who did not use aspirin (47.0 nmol/l, 95% CI: 37.8–58.3) (p = 0.645). Also 
no difference was found in the adjusted mean levels of tryptophan between patients who 
used aspirin (33.9 μmol/l, 95% CI: 29.6–38.8) and patients who did not use aspirin (33.1 
μmol/l, 95% CI: 29.2–37.6) (p = 0.816).
In the group with a delirium, unadjusted levels of neopterin seemed to be lower in 
patients who used aspirin than in those who did not, as shown in ﬁgure 1. However, in 
this small group the adjusted mean levels of neopterin were not statistically signiﬁcantly 
lower in patients who used aspirin (71.1 nmol/l, 95% CI: 43.8–115.6) than in patients who 
did not use aspirin (77.8 nmol/l, 95% CI: 52.4–115.6) (p = 0.779). In addition, unadjusted 
levels of tryptophan seemed to be higher in patients who used aspirin than in those who 
did not (ﬁgure 1). However, the adjusted mean levels of tryptophan were not statistically 
signiﬁcantly higher in patients who used aspirin (27.3 μmol/l, 95% CI: 18.4–40.5) than in 
those who did not (22.4 μmol/l, 95% CI: 16.2–30.9) (p = 0.439).
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Table 1. Demographic and clinical baseline characteristics of the study participants
Variable No delirium (n = 58) Delirium (n = 22) p-value
Male 28 (48.3) 9 (40.9) 0.555 a
Age in years 80.4 ± 7.5 85.8 ± 4.1 0.002 c
MMSE score e 25.0 (22.0–28.0) 20.0 (17.3–24.3) 0.000 b
Katz ADL score f 0.0 (0.0–3.0) 3.5 (1.0–11.3) 0.013 b
OARS-IADL score g 5.0 (0.0–10.0) 10.0 (3.0–14.0) 0.037 b
Barthel Index h 18.0 (13.0–20.0) 16.0 (9.0–19.0) 0.050 b
ISAR score i 4.0 (2.5–6.0) 6.0 (5.0–7.0) 0.000 b
Charlson Comorbidity Index j 2.00 (1.00–3.00) 2.00 (1.00–3.25) 0.202 b
eGFR (ml/min) 64.3 ± 25.3 48.0 ± 24.7 0.011 c
Aspirin at admission 27 (46.6) 9 (40.9) 0.651 a
Type of aspirin:
 Acetylsalicylic acid 12 (44.4) 5 (55.6)
 Carbasalate calcium 15 (55.6) 4 (44.4)
Beta-blockers 17 (29.3) 6 (27.3) 0.857 a
Diuretics 22 (37.9) 7 (31.8) 0.612 a
ACE inhibitors 14 (24.1) 6 (27.3) 0.772 a
Angiotensin II receptor antagonists 8 (13.8) 2 (9.1) 0.719 d
Calcium channel blockers 13 (22.4) 3 (13.6) 0.536 d
Nitrates 5 (8.6) 1 (4.5) 1.000 d
Statins 27 (46.6) 3 (13.6) 0.007 a
Dipyridamole 5 (8.6) 0 (0.0) 0.315 d
Notes: Values are expressed as mean ± SD for normally distributed continuous variables, median (inter-
quartile range) for not normally distributed continuous variables and n (percentages) for categorical vari-
ables. a Chi-square test. b Mann-Whitney U-test. c Student’s t-test. d Fisher’s exact test. e range 0 (severe 
cognitive impairment) to 30 (no cognitive impairment). f range 0 (no disability) to 12 (severe disability). g 
range 0 (no disability) to 14 (severe disability). h range 0 (severe disability) to 20 (no disability). i scores t 
2 indicate a high risk for functional decline. j range 0 to 37 (severe burden of comorbidities).
Abbreviations: ACE, angiotensin converting enzyme; ADL, Activities of Daily Living; eGFR, estimated 
glomerular ﬁltration rate; ISAR, Identiﬁcation of Seniors at Risk; MMSE, Mini-Mental State Examination; 
OARS-IADL, Older Americans Resource Scale for Instrumental Activities of Daily Living.
Table 2. Neopterin levels (nmol/l) in patients with and without a delirium, stratiﬁed for the use of aspirin
No delirium No aspirin (n = 31) Aspirin (n = 27) p-value
Model 1 45.8 (36.2–57.9) 44.9 (34.9–57.8) 0.908
Model 2 47.0 (37.8–58.3) 43.6 (34.5–55.0) 0.645
Delirium No aspirin (n = 13) Aspirin (n = 9) p-value
Model 1 88.3 (57.7–135.2) 59.3 (35.6–98.9) 0.228
Model 2 77.8 (52.4–115.6) 71.1 (43.8–115.6) 0.779
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 
values. Model 1: not adjusted. Model 2: adjusted for age, sex, Charlson Comorbidity Index, statin use 
and the estimated glomerular ﬁltration rate.
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Figure 1. Unadjusted levels of neopterin and tryptophan in patients with and without delirium who used 
(+) or did not use (-) aspirin. Lines are medians.
DISCUSSION
In the present study, we found that the use of aspirin (exclusively low dose aspirin) was 
not associated with a decreased prevalence of delirium. Furthermore, we found that mean 
neopterin and tryptophan levels were not statistically signiﬁcant affected by the use of 
aspirin in patients with and without a delirium.
As far as we are aware, this is the ﬁrst study investigating the possible association be-
tween aspirin use and mean neopterin and tryptophan levels in patients with and without 
a delirium. We found that neopterin and tryptophan levels were not statistically signiﬁcant 
affected by the use of aspirin. Therefore, we could not conﬁrm the relationship found in 
vitro by Schroecksnadel et al. that aspirin decreases neopterin production as well as tryp-
tophan degradation. These controversial ﬁndings may be caused by several factors. First, 
Schroecksnadel et al. found that the inhibition of neopterin production and tryptophan 
degradation by aspirin was dose-dependent [7]. In our study, all aspirin users used acetyl-
salicylic acid or carbasalate calcium in a low dose within cardiovascular risk management 
(80 and 100 mg a day, respectively). It might be possible that these dosages are too low for 
having a signiﬁcant effect on neopterin and tryptophan levels. Another possibility is that 
Table 3. Tryptophan levels (μmol/l) in patients with and without a delirium, stratiﬁed for the use of 
aspirin
No delirium No aspirin (n = 31) Aspirin (n = 27) p-value
Model 1 33.8 (29.6–38.6) 33.1 (28.7–38.2) 0.835
Model 2 33.1 (29.2–37.6) 33.9 (29.6–38.8) 0.816
Delirium No aspirin (n = 13) Aspirin (n = 9) p-value
Model 1 21.6 (15.4–30.3) 28.8 (19.2–43.2) 0.269
Model 2 22.4 (16.2–30.9) 27.3 (18.4–40.5) 0.439
Notes: Values are expressed as mean (95% conﬁdence interval) and are the back-transformed log10 val-
ues. Model 1: not adjusted. Model 2: adjusted for age, sex, Charlson Comorbidity Index and statin use.
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we did not ﬁnd an association due to the small sample size. However, in the group with a 
delirium, neopterin levels seemed to be lower and tryptophan levels seemed to be higher in 
patients who used aspirin than in those who did not. Therefore, it might be possible that in 
a larger group these differences would become statistically signiﬁcant. On the other hand, 
this trend was not seen in the group without a delirium. Schroecksnadel et al. found that 
aspirin did not inﬂuence tryptophan degradation and only minimally affected neopterin 
production in resting cells [7]. It might be possible that in patients without a delirium 
neopterin production and tryptophan degradation was not stimulated enough and that 
we, therefore, did not see a trend in this group.
The potential inﬂuence of aspirin on neopterin production and tryptophan degradation 
in patients with a delirium might be the result of a modulating effect of aspirin on the 
cytokine IFN-γ. Both the production of neopterin as well as the degradation of tryptophan 
is IFN-γ dependent. During immune activation, IFN-γ induces in macrophages the enzyme 
guanosine triphosphate cyclohydrolase-I, which is among others responsible for the pro-
duction of neopterin [4, 5]. IFN-γ also induces the enzyme indoleamine-2,3-dioxygenase 
which converts tryptophan to kynurenine [19]. In a previous study performed in a chimeric 
mouse model of giant cell arteritis, aspirin has been demonstrated to be highly effective in 
suppressing IFN-γ production at doses of 20–100 mg/kg [20]. However, the doses used in 
that study were much higher than the dose used by our participants and therefore it might 
be expected that the ﬁndings are only generalizable to a lesser extent to the dose used in 
our study. Interestingly, they also found that another NSAID, indomethacin, was not able 
to reduce IFN-γ transcription [20]. This might suggest that NSAIDs which are structurally 
unrelated to aspirin are not able to affect neopterin and tryptophan levels. In line with 
this hypothesis, Forrest et al. found in patients with osteoporosis after two years of drug 
treatment that additional pain treatment with a NSAID did not decrease neopterin levels 
and did not increase tryptophan levels in comparison with patients who did not use NSAIDs 
[21]. The authors note that patients taking NSAIDs might be among the more severely 
affected patients in whom disease control could be difﬁcult and this could have inﬂuenced 
their results [21].
Furthermore, we found that the use of aspirin was neither associated with a decreased 
nor with an increased prevalence of delirium, despite it has been speculated that NSAIDs 
increase the risk of a delirium. In a systematic review, it was found that research on the 
association of NSAIDs with delirium is limited and that the association remains uncertain 
[22]. It is important to note that in the present study the association between the use of 
low dose aspirin and delirium was evaluated. Therefore, it might be still possible that other 
NSAIDs are associated with an increased risk of a delirium.
Chapter 3.1
94
Limitations and strengths
This study has some limitations. First, the cross-sectional design limits the ability to identify 
a causal relationship between aspirin use, neopterin and tryptophan levels, and the preva-
lence of delirium. Therefore, the results of this study should be considered as hypothesis 
generating. Second, the relatively small sample size decreased the ability to detect a pos-
sible association between aspirin use and mean neopterin and tryptophan levels in patients 
with a delirium. Third, delirium severity was not scored in our study. It might be possible 
that the use of aspirin does not prevent delirium, but that it will decrease delirium severity 
(as aspirin really inhibits neopterin production and tryptophan degradation as it seems). 
Fourth, tryptophan levels could be inﬂuenced by dietary intake. In this study, we were 
not able to adjust for dietary status and this might have inﬂuenced our results. However, 
since possible food intake was random and blood was collected between 8 and 10 a.m., 
we think that our results are only minimally inﬂuenced by this. Finally, we were not able 
to evaluate whether the use of NSAIDs other than aspirin will have a potential inﬂuence 
on neopterin and tryptophan levels. Since other NSAIDs, used to treat inﬂammation and 
pain, are only limited prescribed to elderly patients due to their negative effects on renal 
function, it would probably only be interesting to investigate this for diseases in a younger 
population in which neopterin and tryptophan are also involved and not for delirium in 
elderly patients.
The present study has several strengths. First, the intensive monitoring of clinical symp-
toms of patients with a delirium until discharge and the DSM-IV diagnosis by a geriatrician 
makes it less likely that we missed a delirium or misdiagnosed symptoms. Second, we have 
performed statistical analyses in a relatively homogeneous group of patients, since all of 
them used low dose aspirin.
CONCLUSION
In this study in older, acutely ill hospitalized patients, we did not ﬁnd a statistically signiﬁ-
cant effect of aspirin use on neopterin and tryptophan levels in patients with and without 
a delirium. However, in patients with a delirium, neopterin levels seemed to be lower and 
tryptophan levels seemed to be higher in patients who used aspirin compared with those 
who did not. Larger studies might be needed to investigate this potential inﬂuence of as-
pirin use on neopterin production and tryptophan degradation in patients with a delirium.
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ABSTRACT
Several studies investigated the possible association between anticholinergic drugs and 
diverse clinical outcomes in older persons, but the results are inconsistent. The aim of this 
study was to investigate whether anticholinergic drug exposure is associated with delirium 
on admission, length of hospital stay, postdischarge institutionalization and in-hospital 
mortality in acutely ill hospitalized older patients. In this observational chart review study, 
we included acutely ill patients aged 65 and older who were admitted to the geriatric ward 
of the Erasmus University Medical Center, Rotterdam, the Netherlands, between 2012 
and 2015 (n = 905). Anticholinergic drug exposure on admission was deﬁned as the use 
of anticholinergic drugs, total number of anticholinergic drugs and anticholinergic drug 
burden score (ADB), quantiﬁed with the Anticholinergic Risk Scale (ARS), the Anticholin-
ergic Cognitive Burden scale (ACB) and the list of Chew et al. (Chew). Logistic regression 
analyses were performed to investigate possible associations between anticholinergic drug 
exposure and the aforementioned outcomes. Analyses were adjusted for age, sex, comor-
bidities, non-anticholinergic drugs and delirium, where appropriate. Moderate and high 
ADB measured with the ARS were associated with delirium on admission with odds ratios 
(OR) of 1.70 (95% conﬁdence interval (CI): 1.16–2.49) and 1.83 (95% CI: 1.06–3.15), 
respectively. High ADB measured with the ARS was also associated with postdischarge 
institutionalization (OR = 2.43, 95% CI: 1.24–4.75). No associations were found using the 
ACB and Chew. Future studies are warranted to investigate the clinical usefulness of the 
ARS in reducing complications in older persons.
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INTRODUCTION
Drugs with anticholinergic properties are commonly prescribed in older persons [1]. These 
drugs are associated with a wide spectrum of adverse effects including dizziness, blurred 
vision, urinary retention, constipation, confusion and possibly also delirium [1]. Older 
persons are more susceptible to those adverse effects due to an age-related increase in 
blood-brain barrier permeability, a reduction in hepatic and renal clearance and a decrease 
in cholinergic neurons and receptors [1-3].
It has been hypothesized that adverse effects of anticholinergic drugs can restrict older 
persons in performing daily activities and lead to hospitalizations, longer length of hos-
pital stay (LOS) and even death (e.g., due to falls). Additionally, a decline in the ability 
to perform daily activities may increase the need for institutionalization in older persons 
[4]. Several studies have investigated the possible association between anticholinergic 
drugs and delirium, LOS, physical function and mortality, but the results are inconsistent 
[5-9]. This discrepancy might be caused by the methods used to assess anticholinergic 
drug use, which differ substantially between studies [6]. In some studies, anticholinergic 
drug use is assessed with crude measures such as ‘exposed or not exposed’ and the total 
number of anticholinergic drugs taken by a person, whereas in other studies the speciﬁc 
anticholinergic load of the different drugs is taken into account. However, little is known 
about potential differences in results between these methods and whether the results 
can be compared. To the best of our knowledge, no previous study has investigated the 
association between anticholinergic drugs and postdischarge institutionalization in acutely 
ill older patients.
The aim of the study was to investigate whether anticholinergic drug exposure on admis-
sion quantiﬁed according to three anticholinergic drug scales is associated with delirium 
on admission, LOS, postdischarge institutionalization and in-hospital mortality in acutely ill 
older patients admitted to a geriatric ward.
MATERIALS AND METHODS
In this observational chart review study, we included acutely ill patients aged 65 and older 
who were admitted to the ward of geriatrics of the Erasmus University Medical Center, 
Rotterdam, the Netherlands, between 1 January 2012 and 31 December 2015. Patients 
were excluded if they were hospitalized for less than 3 days or if data regarding drug 
use or outcome measures were not available. Individual persons could be included more 
than once as patient in the study. The study was conducted according to the principles 
expressed in the Declaration of Helsinki.
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Demographic and clinical variables
All data were collected from the medical records and included age, sex, the estimated 
glomerular ﬁltration rate (eGFR) on admission, drug use at the time of admission and the 
severity of comorbidities calculated with the Charlson Comorbidity Index (CCI) [10]. The 
CCI encompasses 19 medical conditions weighted with a score of 1–6, with total scores 
ranging from 0 to 37, with higher scores indicating a more severe burden of comorbidities. 
Data collected to determine outcome measures were: delirium status during the hospital 
stay, dates of admission and discharge, place of residence before and after discharge and 
in-hospital mortality.
Anticholinergic drug exposure
Dispensing records from the community pharmacy were preferentially used for recording 
all drugs in use by a patient at the time of admission. If this information was not avail-
able, we used correspondence letters of general practitioners or other referrers, or the 
medication history taken in the hospital. This information was additionally combined with 
patients’ self-reports on over-the-counter drugs (reported in the medical record). When a 
drug was stopped 1 or more days prior to admission, we assessed whether there was a 
possibility that the drug was still present in a patient’s body at the time of admission by 
calculating a time window of 5x the elimination half-life of the drug.
Several anticholinergic drug scales have been developed previously that classify drugs 
according to their anticholinergic activity into four or ﬁve categories, ranging from no 
anticholinergic activity (score 0) to strong anticholinergic activity (score 3 or 4) [11]. Three 
of them, the Anticholinergic Risk Scale (ARS) [12], the updated version of the Anticholin-
ergic Cognitive Burden (ACB) scale [13] and the list of Chew et al. [14] (hereafter called 
Chew), were used in the present study. Shortly, on the ARS, drugs are ranked based on 
their potential to cause central and peripheral anticholinergic adverse effects (score range: 
0–3). Drugs assigned a score of 1 have a moderate anticholinergic potential and drugs with 
scores 2 and 3 have a strong and very strong potential, respectively. On the ACB, drugs are 
ranked based on their potential to have a negative effect on cognition (score range: 0–3). 
Drugs with a score of 1 are those with serum anticholinergic activity or in vitro afﬁnity to 
muscarinic receptors, but without known clinically relevant cognitive effects. Drugs with 
established and clinically relevant cognitive anticholinergic effects were assigned a score 
of 2 or 3 [13, 15]. On the Chew, drugs are ranked based on in vitro serum anticholinergic 
activity measurements (score range: 0–3). Drugs with a score of 0.5 have an estimated an-
ticholinergic activity of 0 at therapeutic doses, but may demonstrate some anticholinergic 
activity at higher doses. Drugs with a score of 1–3 demonstrate low to high anticholinergic 
activity across the therapeutic range [14].
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In the present study, anticholinergic drug exposure on admission was deﬁned as the use 
of drugs with anticholinergic properties, total number of anticholinergic drugs and total 
anticholinergic drug burden score (ADB), all quantiﬁed with the three anticholinergic drug 
scales. The ADB is the sum of scores assigned to each drug a patient is taking.
Outcome measures
The outcomes of interest were delirium on admission, LOS, postdischarge institutionaliza-
tion and in-hospital mortality. On the ward of geriatrics, the diagnosis of delirium is made 
by geriatricians as part of daily clinical practice, according to the criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, 4th and 5th edition [16, 17] and is based on daily 
psychiatric examination, medical and nursing notes, the Delirium Observation Screening 
scale scores, and information given by the patient’s closest relative. In this study, reported 
diagnoses of delirium were extracted from the medical records. Delirium was deﬁned as 
“present on admission” if the diagnosis was made within the ﬁrst 2 days of the hospital 
stay. All other patients were considered as not having delirium on admission.
LOS was deﬁned as the number of days a patient was hospitalized, with the ﬁrst day 
of admission as day one. Patients who died during the hospital stay were not included in 
analyses of LOS.
Postdischarge institutionalization was deﬁned as discharge to an institutional care facility 
rather than discharge to home. Patients who resided in an institutional care facility before 
admission and patients who died during the hospital stay were not included in analyses 
regarding postdischarge institutionalization.
In-hospital mortality was recorded; all patients were included in the analyses.
Statistical analyses
Differences in characteristics between patients with and without delirium on admission 
were compared using the Chi-square test for categorical variables, the Mann–Whitney U-
test for non-normally distributed continuous variables and the Student’s t-test for normally 
distributed continuous variables.
Logistic regression analysis was performed to calculate odds ratios (OR) and corre-
sponding 95% conﬁdence intervals (CI) for delirium on admission, LOS, postdischarge 
institutionalization and in-hospital mortality (dependent variables) according to different 
measures of anticholinergic drug exposure (exposure no/yes, total number of anticholin-
ergic drugs and categories of ADB quantiﬁed with the ARS, the ACB and the Chew). LOS 
was divided into two groups based on the median value found in the overall sample (8.0 
days). Number of anticholinergic drugs was treated as a continuous variable. ADB was 
divided into three categories: no ADB (for all scales score 0), moderate ADB (ARS and ACB 
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score 1–2; Chew score 0.5–1.0) and high ADB (ARS and ACB score t 3; Chew score t 
1.5); the ﬁrst category was used as reference. All analyses were adjusted for age, sex, CCI 
and number of non-anticholinergic drugs. Analyses of LOS, postdischarge institutionaliza-
tion and in-hospital mortality were additionally adjusted for delirium at any time during 
the hospital stay. Subsequently, analyses of LOS, postdischarge institutionalization and 
in-hospital mortality were repeated in the group of patients with delirium on admission. 
Considering the suggested cholinergic deﬁciency in delirium [18] and the high prevalence 
of prolonged LOS, postdischarge institutionalization and in-hospital mortality in patients 
with delirium [19, 20], we hypothesized that the effect of anticholinergic drug exposure 
on aforementioned outcomes would be different in acutely ill older patients with delirium. 
LOS was divided into two groups based on the median value found in this group (10.0 
days). Analyses were adjusted for age, sex, CCI and number of non-anticholinergic drugs.
Repeated measures logistic regression models were ﬁtted for all outcome measures us-
ing the Generalized Estimating Equations (GEE) method, to examine the effect of multiple 
inclusions per individual on the calculated estimates. Models were adjusted for the same 
covariates as the main analyses.
All statistical analyses were performed using Statistical Package for the Social Sciences 
(SPSS), version 21.0 (IBM Corp., Armonk, NY). Results were considered statistically signiﬁ-
cant at a p < 0.05.
RESULTS
A total of 1193 patients were admitted during the study period, of which 165 did not 
meet the inclusion criteria. Of the remaining 1028 patients, 123 were excluded: 119 were 
hospitalized for less than 3 days and four had unclear data regarding drug use or outcome 
measures. In total, 905 patients were included in the study; 215 of them (23.8%) had 
delirium on admission (ﬁgure 1). No statistically signiﬁcant differences were found in sex 
distribution (men: 48.3% versus 41.5%, p = 0.155) and mean age (81.0 ± 7.0 versus 
81.0 ± 7.5, p = 0.966) between patients who were included and those who were not. 
Baseline and discharge characteristics of the included patients are outlined in table 1. The 
frequency distributions of the total number of anticholinergic drugs and the ADB scores 
among patients are presented in ﬁgures S1 and S2 of the Supplementary material.
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Figure 1. Flow chart of study sample selection.
Delirium and length of stay
Table 2 presents the ORs and corresponding 95% CIs for delirium on admission and LOS t 
9 days according to different measures of anticholinergic drug exposure. After adjustment 
for age, sex, CCI and number of non-anticholinergic drugs, we found that exposure to 
anticholinergic drugs according to the ARS was associated with an increased odds of hav-
ing delirium on admission (OR = 1.73, 95% CI: 1.23–2.45). Each additional anticholinergic 
drug used by a patient was associated with a 38% increase in odds of having delirium on 
admission (OR = 1.38, 95% CI: 1.10–1.73). Both moderate and high ADB measured with 
the ARS were associated with an increased odds of having delirium on admission when 
compared to no ADB (OR = 1.70, 95% CI: 1.16–2.49 and OR = 1.83, 95% CI: 1.06–3.15, 
respectively). No associations were found between anticholinergic drug exposure quanti-
ﬁed with the ACB and the Chew, and delirium.
After adjustment for age, sex, CCI, number of non-anticholinergic drugs and delirium 
at any time during the hospital stay, no associations were found between anticholinergic 
drug exposure and LOS.
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Table 1. Baseline and discharge characteristics of the overall study sample and stratiﬁed for delirium on 
admission.
Characteristic
Overall sample
(n = 905)
No delirium
(n = 690)
Delirium
(n = 215) p-value a
Male, n (%) 437 (48.3) 316 (45.8) 121 (56.3) 0.007 b
Age, years, mean ± SD 81.0 ± 7.03 80.7 ± 7.1 81.9 ± 6.7 0.022 c
Place of residence before admission, n (%) 0.035 b
 Home (with or without home care) 696 (76.9) 542 (78.6) 154 (71.6)
 Institutional care facility 209 (23.1) 148 (21.4) 61 (28.4)
First time on the ward of geriatrics, n (%) 580 (64.1) 426 (61.7) 154 (71.6) 0.008 b
CCI, median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 3.0 (1.0–4.0) 0.678 d
eGFR, ml/min, median (IQR) 54.0 (35.0–75.0) 54.0 (35.0–75.0) 53.0 (36.0–74.0) 0.918 d
Number of drugs, median (IQR) 8.0 (6.0–12.0) 8.0 (6.0–12.0) 8.0 (6.0–12.0) 0.963 d
Use of at least one DAP, n (%)
 ARS 256 (28.3) 180 (26.1) 76 (35.3) 0.009 b
 ACB 644 (71.2) 488 (70.7) 156 (72.6) 0.605 b
 Chew 523 (57.8) 399 (57.8) 124 (57.7) 0.969 b
Number of DAPs, median (IQR)
 ARS 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.011 d
 ACB 1.0 (0.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.383 d
 Chew 1.0 (0.0–1.0) 1.0 (0.0–1.0) 1.0 (0.0–1.0) 0.585 d
ADB score, median (IQR)
 ARS 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.015 d
 ACB 1.0 (0.0–3.0) 1.0 (0.0–3.0) 1.0 (0.0–3.0) 0.118 d
 Chew 0.5 (0.0–1.0) 0.5 (0.0–1.0) 0.5 (0.0–1.0) 0.474 d
Delirium developed during the hospital stay, 
n (%)
45 (5.0) 45 (6.5) n/a n/a
Place of residence after discharge, n (%) < 0.001 b
 Home (with or without home care) 448 (49.5) 389 (56.4) 59 (27.4)
 Institutional care facility 392 (43.3) 260 (37.7) 132 (61.4)
In-hospital mortality, n (%) 65 (7.2) 41 (5.9) 24 (11.2) 0.010 b
Length of stay, days, median (IQR) 8.0 (5.0–11.0) 7.0 (5.0–11.0) 10.0 (7.0–14.0) < 0.001 d
Notes: a No Delirium versus Delirium. b Chi-square test. c Student’s t-test. d Mann-Whitney U-test.
Abbreviations: ACB, Anticholinergic Cognitive Burden scale; ADB, Anticholinergic Drug Burden; ARS, 
Anticholinergic Risk Scale; CCI, Charlson Comorbidity Index (range 0-37); DAP, drug with anticholinergic 
properties; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; SD, standard deviation.
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Table 2. Odds ratios for delirium on admission and prolonged length of hospital stay according to differ-
ent measures of anticholinergic drug exposure.
Variable
Delirium on admission LOS t 9 days
Delirium/no delirium OR (95% CI) a LOS t 9/LOS < 9 OR (95% CI) b,c
ARS
Exposure to DAPs
 No 139/510 1.00 (ref) 274/330 1.00 (ref)
 Yes 76/180 1.73 (1.23–2.45) 114/122 1.06 (0.77–1.48)
Number of DAPs
 Per drug 215/690 1.38 (1.10–1.73)  388/452 0.99 (0.79–1.24) 
ADB score
 0 139/510 1.00 (ref) 274/330 1.00 (ref)
 1-2 52/121 1.70 (1.16–2.49) 75/84 1.00 (0.69–1.45)
 t3 24/59 1.83 (1.06–3.15) 39/38 1.23 (0.73–2.07)
ACB
Exposure to DAPs
 No 59/202 1.00 (ref) 113/133 1.00 (ref)
 Yes 156/488 1.10 (0.77–1.59) 275/319 0.99 (0.71–1.38)
Number of DAPs
 Per drug 215/690 1.07 (0.94–1.23) 388/452 0.93 (0.82–1.06)
ADB score
 0 59/202 1.00 (ref) 113/133 1.00 (ref)
 1-2 91/311 0.99 (0.67–1.46) 170/199 0.98 (0.70–1.39)
 t3 65/177 1.39 (0.89–2.18) 105/120 0.99 (0.66–1.51)
Chew
Exposure to DAPs
 No 91/291 1.00 (ref) 161/193 1.00 (ref)
 Yes 124/399 1.09 (0.78–1.51) 227/259 1.10 (0.81–1.49)
Number of DAPs
 Per drug 215/690 1.11 (0.94–1.31) 388/452 0.95 (0.82–1.12)
ADB score
 0 91/291 1.00 (ref) 161/193 1.00 (ref)
 0.5-1 82/285 1.00 (0.71–1.43) 161/182 1.11 (0.81–1.54)
 t1.5 42/114 1.34 (0.85–2.11) 66/77 1.05 (0.69–1.62)
Notes: Values in bold are statistically signiﬁcant (p < 0.05). a Model adjusted for age, sex, Charlson 
Comorbidity Index and non-anticholinergic drugs. b Model adjusted for age, sex, Charlson Comorbidity 
Index, non-anticholinergic drugs and delirium at any time during the hospital stay. c Patients who died 
during the hospital stay were excluded.
Abbreviations: ACB, Anticholinergic Cognitive Burden scale; ADB, Anticholinergic Drug Burden; ARS, 
Anticholinergic Risk Scale; CI, conﬁdence interval; DAPs, drugs with anticholinergic properties; LOS, 
length of hospital stay; OR, odds ratio.
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GEE logistic regression models for delirium on admission and LOS showed that the inclu-
sion of individuals multiple times did not affect the estimates (data not shown).
Postdischarge institutionalization and in-hospital mortality
Table 3 presents the ORs and corresponding 95% CIs for postdischarge institutionalization 
and in-hospital mortality according to different measures of anticholinergic drug exposure. 
After adjustment for age, sex, CCI, number of non-anticholinergic drugs and delirium 
at any time during the hospital stay, we found that each additional anticholinergic drug 
used by a patient according to the ARS was associated with a 38% increase in odds of 
being institutionalized after discharge (OR = 1.38, 95% CI: 1.02–1.86). Additionally, a 
high ADB quantiﬁed with the ARS was associated with a 2.43 times higher odds of being 
institutionalized after discharge in comparison to no ADB (OR = 2.43, 95% CI: 1.24–4.75). 
No associations were found between anticholinergic drug exposure quantiﬁed with the 
ACB and the Chew, and postdischarge institutionalization.
After adjustment for age, sex, CCI, number of non-anticholinergic drugs and delirium at 
any time during the hospital stay, no associations were found between anticholinergic drug 
exposure and in-hospital mortality.
GEE logistic regression models for postdischarge institutionalization and in-hospital mor-
tality showed that the inclusion of individuals multiple times did not affect the estimates 
(data not shown).
Analyses in patients with delirium on admission
Table 4 presents the ORs and corresponding 95% CIs for LOS t 11 days, postdischarge 
institutionalization and in-hospital mortality according to different measures of anticho-
linergic drug exposure in patients with delirium on admission. The association between 
anticholinergic drug exposure and postdischarge institutionalization found in the total 
group of acutely ill patients was not maintained in this subgroup. No associations were 
found between anticholinergic drug exposure and LOS and in-hospital mortality.
GEE logistic regression models for the three outcome measures showed that the inclu-
sion of individuals multiple times did not affect the estimates (data not shown).
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Table 3. Odds ratios for postdischarge institutionalization and in-hospital mortality according to different 
measures of anticholinergic drug exposure.
Variable
Postdischarge institutionalization In-hospital mortality
Institutionalized/home OR (95% CI) a,b Dead/alive OR (95% CI) a
ARS
Exposure to DAPs
 No 151/333 1.00 (ref) 45/604 1.00 (ref)
 Yes 63/110 1.43 (0.95–2.14) 20/236 1.20 (0.67–2.15)
Number of DAPs
 Per drug 214/443 1.38 (1.02–1.86)  65/840 1.07 (0.73–1.58) 
ADB score
 0 151/333 1.00 (ref) 45/604 1.00 (ref)
 1-2 40/81 1.17 (0.74–1.85) 14/159 1.20 (0.63–2.29)
 t3 23/29 2.43 (1.24–4.75) 6/77 1.22 (0.47–3.13)
ACB
Exposure to DAPs
 No 72/129 1.00 (ref) 15/246 1.00 (ref)
 Yes 142/314 0.84 (0.56–1.25) 50/594 1.51 (0.80–2.84)
Number of DAPs
 Per drug 214/443 0.94 (0.80–1.11)  65/840 1.13 (0.90–1.41) 
ADB score
 0 72/129 1.00 (ref) 15/246 1.00 (ref)
 1-2 85/207 0.73 (0.48–1.12) 33/369 1.52 (0.79–2.93)
 t3 57/107 1.12 (0.68–1.86) 17/225 1.47 (0.66–3.25)
Chew
Exposure to DAPs
 No 99/202 1.00 (ref) 28/354 1.00 (ref)
 Yes 115/241 1.15 (0.80–1.67) 37/486 1.11 (0.64–1.91)
Number of DAPs
 Per drug 214/443 1.05 (0.85–1.29) 65/840 1.11 (0.84–1.46)
ADB score
 0 99/202 1.00 (ref) 28/354 1.00 (ref)
 0.5-1 81/178 1.09 (0.74–1.62) 24/343 1.01 (0.56–1.83)
 t1.5 34/63 1.37 (0.80–2.36) 13/143 1.39 (0.66–2.92)
Notes: Values in bold are statistically signiﬁcant (p < 0.05). a Model adjusted for age, sex, Charlson Co-
morbidity Index, non-anticholinergic drugs and delirium at any time during the hospital stay. b Patients 
who resided in an institutional care facility before admission and patients who died during the hospital 
stay were excluded.
Abbreviations: ACB, Anticholinergic Cognitive Burden scale; ADB, Anticholinergic Drug Burden; ARS, 
Anticholinergic Risk Scale; CI, conﬁdence interval; DAPs, drugs with anticholinergic properties; OR, odds 
ratio.
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DISCUSSION
In this study, we found that anticholinergic drug exposure, measured with the ARS, is 
associated with an increased prevalence of delirium and increased postdischarge institu-
tionalization in acutely ill hospitalized older patients.
Our ﬁnding that anticholinergic drug exposure measured with the ARS is associated 
with delirium, is in agreement with the results of previous studies performed in critically 
ill patients [21], palliative care patients [22], patients with Parkinson’s disease [23] and 
older nursing home residents [24]. Also, previous studies found no association between 
anticholinergic drug exposure, measured with the ACB or the Anticholinergic Drug Scale, 
and delirium in older hospitalized patients [21, 25, 26]. These ﬁndings strengthen the 
observation that results may differ depending on which scale is used when assessing 
anticholinergic drug exposure.
Several studies have investigated the possible relationship between anticholinergic drug 
exposure and LOS in older hospitalized persons [7-9, 27, 28]. Three of them used the ARS 
and/or ACB and found, in line with our study, no association between anticholinergic 
drug exposure and LOS [7, 27, 28]. Mangoni et al. [9] also used the ARS and found that 
anticholinergic drug exposure was only associated with prolonged LOS in older patients 
who were admitted during a non-heat wave period. In contrast to our study, the previous 
study [9] included only older patients who were discharged home and did not exclude 
patients who were hospitalized for < 3 days. Therefore, it might be speculated that the 
patients included in the study of Mangoni et al. [9] were healthier and probably less frail 
than our study population. Lowry et al. [8] also found that the use of anticholinergic drugs 
was associated with prolonged LOS in older hospitalized persons. However, they used 
an alternate anticholinergic drug scale and had previously found that the ARS was not 
associated with LOS in the same study sample [28].
As far as we are aware this is the ﬁrst study showing an association between anticho-
linergic drug exposure, measured with the ARS, and postdischarge institutionalization in 
acutely ill older patients. In a previous study, no association was found between anticho-
linergic drug use and nursing home admission within one year after hospital discharge 
[29]. However, Narbey et al. [29] did not use an anticholinergic drug scale and treatment 
with anticholinergic drugs can have changed over time. Therefore, caution is warranted in 
extrapolating their results. A possible explanation for our ﬁnding that anticholinergic drug 
exposure, measured with the ARS, is associated with postdischarge institutionalization, 
might be an underlying decrease in functional performance. Several studies have found 
that anticholinergic drug exposure quantiﬁed with the ARS is associated with a reduced 
physical function in older persons [7, 24, 28, 30, 31].
Several studies have investigated the possible association between the use of anticho-
linergic drugs and in-hospital mortality in older patients [8, 9, 27, 28]. Mangoni et al. 
113
Anticholinergic drug exposure and clinical outcomes
3
[9], Kidd et al. [27] and Lowry et al. [8] used the ARS, the ACB and the anticholinergic 
component of the Drug Burden Index respectively, and in line with our study, found no 
association. In a subgroup of older patients with hyponatremia, Lowry et al. [28] reported 
that high ARS scores were associated with increased in-hospital mortality.
To the best of our knowledge, no previous studies investigated the possible association 
between anticholinergic drug use and clinical outcomes in acutely ill hospitalized older 
patients with delirium. Recently, Kolanowski et al. [32] found that the use of anticholiner-
gic drugs according to the ACB was associated with prolonged LOS and reduced physical 
function, but not with discharge disposition in older persons with delirium who resided 
in a postacute care facility. In contrast to our study, their sample size was relatively small, 
all participants had dementia, were not acutely ill, and in the vast majority delirium was 
resolving.
Although no conclusions on causality can be drawn from this observational study, our re-
sults suggest that older persons who are exposed to anticholinergic drugs are at increased 
risk for delirium when they become acutely ill. Additionally, they might be at increased 
risk for postdischarge institutionalization independently of delirium. The question remains 
whether anticholinergic drugs ‘in general’ are associated with delirium and postdischarge 
institutionalization, since only the ARS was associated with them. Discrepancies in results 
between the ARS, ACB and Chew might be related to the large variation in number and 
ranking of drugs within each scale, which is caused by the different methods used to 
develop them. In all anticholinergic drug scales, the calculation of the ADB is based on the 
assumption that anticholinergic effects of different drugs are additive in a linear fashion. 
This might not be the case and therefore, inclusion of drugs without known clinically 
relevant anticholinergic effects might dilute possible associations. Therefore, it might be 
warranted to identify only drugs with established peripheral and cognitive anticholinergic 
effects in future studies. Furthermore, it might be possible that in delirium not only central 
anticholinergic effects may play a role, if any, but also peripheral anticholinergic effects. 
Blurred vision, urinary retention, constipation and confusion are risk factors for delirium 
and might explain why the ARS was associated with delirium. However, since we did not 
collect data on adverse effects, this remains speculative. In patients with delirium, we 
found that the ARS was not associated with postdischarge institutionalization. It might be 
possible that the sample size was too small; other explanations could be that anticholiner-
gic drugs play a minor role, if any, in the clinical course of delirium, or that anticholinergic 
drugs were stopped more frequently after admission since a cholinergic deﬁciency is still 
one of the most hypothesized causes of delirium [18].
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Limitations and strengths
This study has some limitations. First, the study design limits the ability to identify causal 
associations between the use of anticholinergic drugs and the outcome measures. Infor-
mation on any changes in drug exposure during hospitalization was not collected and we 
cannot exclude that the treatment approach for the acute illness has inﬂuenced our results. 
Moreover, other health-related factors, such as the reason for admission, the severity of 
illness, functional status and the degree of cognitive functioning can have inﬂuenced our 
results. In this study, we were not able to score and adjust for the severity of illness and 
physical function, since information on those items was not always available. However, we 
have adjusted for the CCI in statistical models; therefore, we believe that we have provided 
an indirect adjustment for dementia. A comorbid cognitive disturbance, not diagnosed as 
dementia (yet), can still be a confounding factor. Second, the three anticholinergic drug 
scales were developed several years ago (the ARS and the Chew in 2008; the ACB was last 
updated in 2012) and do not include newer anticholinergic drugs. This might have led to 
an underestimation of the anticholinergic drug exposure, but we believe that our results 
are only minimally inﬂuenced by this. Third, the three anticholinergic drug scales do not 
take into account daily drug dose and treatment duration. Since it is likely that anticho-
linergic effects will be ampliﬁed with higher drug doses and longer treatment duration, 
this could have inﬂuenced our results. Fourth, our results are mainly based on information 
on prescribed drugs; minimal information was available on treatment adherence prior to 
hospitalization.
The study has several strengths. First, the ﬁndings were obtained in a relatively large 
sample size. Second, we used three anticholinergic drug scales within the same population 
which makes it possible to make clear comparisons between results. Third, the ARS, ACB 
and Chew provide a quick and simple measure of anticholinergic drug burden and are 
suitable for clinical practice.
CONCLUSION
In this study, we found that anticholinergic drug exposure measured with the ARS, is asso-
ciated with an increased prevalence of delirium on admission and increased postdischarge 
institutionalization in acutely ill hospitalized older patients.
Considering the fact that delirium and postdischarge institutionalization are associated 
with a very poor prognosis, future studies are needed to investigate whether regular 
medication reviews using the ARS are a useful tool in order to reduce complications and to 
preserve independent functioning in older persons.
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Figure S1. Frequency distributions of the number of DAPs on admission for the overall study sample and 
stratiﬁed for delirium on admission.
Abbreviations: ACB, Anticholinergic Cognitive Burden Scale; ARS, Anticholinergic Risk Scale; DAPs, 
drugs with anticholinergic properties.
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GENERAL DISCUSSION
Delirium, an acute neuropsychiatric syndrome, is a common disorder among older 
hospitalized patients and is associated with poor clinical outcomes including prolonged 
hospital stay, loss of independence, increased rates of cognitive decline and mortality [1-3]. 
However, despite the high prevalence and clinical impact, very little is known about the 
underlying pathogenesis. Several mechanisms have been proposed to be involved in the 
pathophysiology of delirium and include, among others, increased activation of the im-
mune system, oxidative stress, loss of neuroprotection and disturbances in several cerebral 
neurotransmitter systems [4]. Also several drugs and drug classes may play a role in the 
pathogenesis of delirium. Many drugs commonly used by older persons interfere with one 
or more of the hypothesized mechanisms and therefore, the use of speciﬁc drugs may 
increase or decrease the risk of developing delirium.
The aims of this thesis were to investigate the association of several biochemical mark-
ers and pharmacological agents with delirium. The ﬁndings can contribute to a better 
understanding of the pathophysiology of delirium and may help to ﬁnd markers for early 
recognition and to improve delirium prediction, prevention and treatment.
The ﬁndings described in this thesis are based on two studies. The ﬁrst study is the 
Delirium In The Old (DITO) study, a cross-sectional study designed to investigate several 
advanced biochemical blood markers in patients with and without delirium. This study 
included 86 patients aged 65 years and older who were acutely admitted to the wards of 
Internal Medicine and Geriatrics of the Erasmus Medical Center and the ward of Geriatrics 
of the Harbor Hospital, Rotterdam, the Netherlands. The second study is a chart-review 
study including 905 patients aged 65 years and older who were acutely admitted to the 
ward of Geriatrics of the Erasmus Medical Center. This study was performed to investigate 
the possible association between the use of anticholinergic drugs and delirium. Addition-
ally, within the framework of this study, we have investigated a relatively novel and easily 
measureable inﬂammatory marker in patients with and without delirium.
In this chapter, the main ﬁndings are discussed and directions for further research are 
presented. Part one of this chapter will focus on the potential role of inﬂammation, oxida-
tive stress, loss of neuroprotection and disturbances in neurotransmitters as well as the 
interplay among these mechanisms in the pathophysiology of delirium. Part two will focus 
on the potential role of pharmacological agents in delirium.
Main findings
Biochemical markers of delirium – potential implications for the pathophysiology
Activation of the immune system is a prominent feature of many conditions associated 
with delirium, suggesting that inﬂammatory mediators may play a role in delirium. Cur-
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rently, the neuroinﬂammatory hypothesis is one of the leading theories with regard to 
the pathophysiology of delirium. This hypothesis suggests that peripheral inﬂammation 
induces activation of microglia and astrocytes in the brain which in turn will release 
pro-inﬂammatory cytokines and neurotoxic factors. These factors may cause neuronal 
and synaptic dysfunction and these neurological changes may subsequently manifest as 
delirium [4].
In chapter 2.1, levels of neopterin, interleukin-6 (IL-6) and insulin-like growth factor-1 
(IGF-1) were compared between acutely ill older patients with and without delirium, as 
markers for immune system activation, oxidative stress and brain reserve. Increased levels 
of neopterin and IL-6 and decreased levels of IGF-1 were found in patients with delirium. 
These ﬁndings might suggest that a disturbed activation of the innate and cellular im-
mune system, oxidative stress and an increased vulnerability of the brain may underlie the 
development of delirium.
So far, limited research has focused on the potential role of neopterin in delirium, but all 
studies currently performed have found increased neopterin levels in plasma or cerebrospi-
nal ﬂuid (CSF) prior to and during delirium [5-7]. This consistency in ﬁndings suggests that 
neopterin might indeed play a role in the pathophysiology of delirium. The physiological 
functions of neopterin in the periphery and central nervous system are, however, virtually 
unknown. Therefore, it remains hypothetical by which mechanisms neopterin might be 
associated with delirium. Considering that neopterin is primarily produced by activated 
macrophages and monocytes (cells that produce reactive oxygen species (ROS)), it seems 
plausible that neopterin induces or enhances cytotoxicity, either directly or indirectly. In 
vitro studies have suggested that neopterin might activate ROS-sensitive transcription fac-
tors [8] and neopterin’s derivative 7,8-dihydroneopterin might be able to induce apoptosis 
in astrocytes and neurons in a dose-dependent manner [9].
Another mechanism exists that might explain why increased neopterin levels are as-
sociated with delirium. During inﬂammation, neopterin production will be accompanied 
by an enhanced conversion of tryptophan to kynurenine in both peripheral and central 
tissue (ﬁgure 1). Kynurenine is able to pass the blood-brain barrier and can be further 
metabolized to kynurenic acid and quinolinic acid. During times of stress and inﬂamma-
tion, the kynurenine pathway preferentially produces quinolinic acid, which is a neurotoxic 
metabolite produced by microglia [10, 11]. Increased production of quinolinic acid can 
lead to neuronal injury, excitotoxicity and apoptosis [12], which may manifest as delirium. 
Increased activation of the kynurenine pathway has been implicated in the pathophysi-
ology of several neurodegenerative and psychiatric disorders [13], including acute brain 
dysfunction during critical illness [14]. Though kynurenine levels were not measured in the 
studies described in this thesis, it might be possible that the observed lower tryptophan 
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levels and tryptophan ratios in patients with delirium (chapter 2.2) might be caused by an 
increased turnover of tryptophan to kynurenine.
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Figure 1. Schematic presentation of the formation of neopterin and kynurenine in response to the 
pro-inﬂammatory cytokine IFN-γ. During inﬂammation, the kynurenine pathway preferentially produces 
quinolinic acid under the inﬂuence of a variety of pro-inﬂammatory mediators which affect several en-
zymes not depicted in this ﬁgure. 
Abbreviations:  GTPCH, guanosine triphosphate cyclohydrolase I; IDO, indoleamine 2,3-dioxygenase; 
IFN-γ, interferon-γ.
Inﬂammation is a complex process in which different cytokines and other inﬂammatory 
mediators interact and the balance between pro- and anti-inﬂammatory responses will de-
termine in which amount the inﬂammatory response will be protective or harmful. During 
peripheral inﬂammation, pro-inﬂammatory cytokines – in particular IL-1β, tumor necrosis 
factor-α (TNF-α) and IL-6 – play an important role in the upregulation of the inﬂamma-
tory response. It is now well established that pro-inﬂammatory cytokines as well as other 
inﬂammatory mediators communicate with the brain via multiple pathways, leading to 
the activation of microglia and astrocytes. Once activated, these cells will secrete several 
cytotoxic factors, such as reactive oxygen species and proteases, and pro-inﬂammatory cy-
tokines which will enhance the inﬂammatory response, but which may also cause neuronal 
and synaptic dysfunction [15].
In patients with delirium, increased levels of pro-inﬂammatory cytokines (e.g. IL-1β 
[16, 17] and IL-6 [5, 18-21]) and decreased levels of anti-inﬂammatory cytokines (e.g. 
IL-1 receptor antagonist [22, 23]) have been found in serum and CSF, but the results are 
inconsistent. Interestingly, a previous study reported that patients who developed delirium 
after elective arthroplasty had an increased ratio of pro-inﬂammatory to anti-inﬂammatory 
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cytokines, suggesting that an imbalance in the inﬂammatory response, in favor of the 
pro-inﬂammatory response, might be involved in delirium [24].
It has also been suggested that an underlying vulnerability of the brain may predispose 
patients to the development of delirium. IGF-1 – a growth factor with neuroprotective 
properties – plays an important role within the central nervous system. IGF-1 promotes 
neuronal proliferation, differentiation and survival; controls synaptogenesis and synaptic 
plasticity and protects neurons against free radical damage [25]. Therefore, decreased IGF-
1 levels may suggest that the brain is more vulnerable to the cytotoxic effects of cytokines 
and other neurotoxic factors.
Several mechanisms might be involved in the pathophysiology of delirium and besides 
inﬂammation and an increased vulnerability of the brain, disturbances in one or more 
cerebral neurotransmitter systems might play a role. The neurotransmitter hypothesis 
suggests that a relative acetylcholine deﬁciency, an excess of dopamine and disturbances 
in serotonin and melatonin (both increased and decreased activity) may underlie the char-
acteristic symptoms seen during delirium [4].
The measurement of cerebral neurotransmitter levels requires the performance of inva-
sive procedures such as lumbar punctures. Alternatively, one can also measure plasma pre-
cursors and/or metabolites as indirect measures for central neurotransmitter functioning.
Serotonin synthesis in the central nervous system is, among others, dependent on the 
availability of its precursor, the large neutral amino acid (LNAA) tryptophan (ﬁgure 2). 
Tryptophan competes with the other LNAAs (phenylalanine, tyrosine, valine, leucine and 
isoleucine) for transport across the blood-brain barrier. The amount of tryptophan that 
eventually enters the brain is determined by the ratio of tryptophan to the sum of the other 
LNAAs (tryptophan/LNAAs ratio). Furthermore, the amino acids phenylalanine and tyrosine 
are the precursors of dopamine (ﬁgure 2). Therefore, the ratios of tyrosine and phenylala-
nine to the other LNAAs are suggestive for the amount of tyrosine and phenylalanine that 
enters the brain.
Tetrahydrobiopterin (BH4) functions as an essential cofactor in several enzymatic reac-
tions involved in the production of serotonin and dopamine (ﬁgure 2) [26]. A change in 
the availability of BH4 may therefore affect the synthesis of these neurotransmitters. The 
phenylalanine/tyrosine ratio is an indirect measure of the BH4 status, as it reﬂects the activ-
ity of the enzyme phenylalanine hydroxylase, an enzyme that uses BH4 as a cofactor [26, 
27]. An elevated ratio of phenylalanine to tyrosine suggests a decreased BH4 availability.
In chapter 2.2, potential disturbances in serotonergic and dopaminergic neurotransmis-
sion during delirium were investigated. For this purpose, peripheral levels of amino acids, 
amino acid ratios and dopamine’s metabolite homovanillic acid (HVA) were investigated. 
Decreased tryptophan/LNAAs ratios and increased phenylalanine/tyrosine ratios were 
found in patients with delirium. These ﬁndings are suggestive for a decreased availability 
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of tryptophan and BH4 for the synthesis of serotonin and consequently might suggest a 
reduced production of serotonin during delirium. No differences in phenylalanine/LNAAs 
ratio, tyrosine/LNAAs ratio and HVA levels were found between patients with and without 
delirium, suggesting that the dopaminergic neurotransmission is not impaired during 
delirium.
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Figure 2. Schematic and simpliﬁed presentation of the biosynthesis of tetrahydrobiopterin (BH4), mono-
amine neurotransmitters and nitric oxide. Due to a relative deﬁciency of PTPS in macrophages and 
monocytes, upregulation of GTPCH by IFN-γ leads to accumulation of 7,8-dihydroneopterin triphosphate 
in the cell, favoring the formation of neopterin. BH4 is an essential cofactor for the aromatic amino acid 
hydroxylases (TPH, PAH and TH) as well as for NOS.
Abbreviations: GTPCH, guanosine triphosphate cyclohydrolase I; PTPS, 6-pyruvoyltetrahydrobiopterin 
synthase; TPH, tryptophan hydroxylase; PAH, phenylalanine hydroxylase; TH, tyrosine hydroxylase; NOS, 
nitric oxide synthase; 5-HIAA, 5-hydroxyindolacetic acid; L-DOPA, L-3,4-dihydroxyphenylalanine; HVA, 
homovanillic acid.
Instead of determining ratios of cytokines that reﬂect different components of the immune 
system (as suggested before), it is also possible to determine ratios of different immune 
cells. The neutrophil-lymphocyte ratio (NLR) represents the balance between neutrophils 
and lymphocytes and integrates two components of the immune system in one marker. 
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Neutrophils play an important role in the immediate response against tissue damage and 
pathogens [28], whereas lymphocytes play an important role in the regulation of an ap-
propriate inﬂammatory response. In various pathological conditions, elevated NLR levels 
have been found to be an independent predictor of disease severity and poor prognosis. 
Moreover, NLR seems to be a more powerful predictor of adverse outcomes than conven-
tional inﬂammatory markers, such as the total white blood cell (WBC) count, the individual 
WBC subtypes and C-reactive protein (CRP) [29-32].
In chapter 2.3, a pilot study is presented in which levels of NLR were investigated in 
patients with and without delirium. Patients with delirium had increased NLR levels, even 
after adjustment for inﬂammatory markers and additionally, no differences were found 
in the levels of CRP, WBC, neutrophils and lymphocytes. These ﬁndings might suggest an 
independent role of NLR in delirium above conventional inﬂammatory markers and support 
the hypothesis that an inadequate response of the immune system and oxidative stress 
may play a role in the pathogenesis of delirium.
Considering that different combinations of predisposing and precipitating factors can lead 
to delirium, it seems likely that the underlying pathophysiological mechanisms may differ 
between groups of patients with delirium. In chapter 2.4, mean levels of neopterin, amino 
acids, amino acid ratios and HVA in acutely ill medical patients with delirium and patients 
with delirium after elective cardiac surgery were compared. Higher neopterin levels and 
higher phenylalanine/tyrosine ratios were found in acutely ill medical patients with de-
lirium than in patients with delirium after cardiac surgery. Differences in determinants 
of neopterin were found between the two groups. The ﬁndings suggest that, in acutely 
ill medical patients, neopterin levels are mainly determined by a cell-mediated immune 
response and oxidative stress, whereas in elective cardiosurgical patients neopterin levels 
are mainly driven by renal function/ﬂuid status. This study highlights that levels of certain 
potential biomarkers for delirium can vary in different groups of patients and suggests that 
the markers and pathways that might be involved in the pathophysiology of delirium in 
acutely ill medical patients may differ from those in elective cardiosurgical patients.
Pharmacological agents
Several drugs commonly used by older persons can interfere with one or more of the 
hypothesized mechanisms underlying delirium and therefore, the use of speciﬁc drugs may 
increase or decrease the risk of developing delirium.
In patients with delirium, increased plasma neopterin levels and a decreased availability 
of tryptophan to the brain were found (chapters 2.1 and 2.2). It has been reported that 
treatment of stimulated peripheral blood mononuclear cells with aspirin (acetylsalicylic 
acid) can signiﬁcantly inhibit neopterin production and tryptophan degradation in vitro 
[33]. The potential inﬂuence of acetylsalicylic acid on neopterin production and trypto-
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phan degradation might be the result of a modulating effect of acetylsalicylic acid on the 
cytokine interferon-gamma (IFN-γ), since both the production of neopterin as well as the 
degradation of tryptophan are IFN-γ dependent (ﬁgure 1). It is unknown whether the use 
of acetylsalicylic acid can inﬂuence neopterin and tryptophan levels in vivo.
In chapter 3.1, the possible association between the use of acetylsalicylic acid and mean 
neopterin and tryptophan levels in patients with and without delirium was investigated. 
The use of acetylsalicylic acid had no statistically signiﬁcant effect on the mean levels of 
neopterin and tryptophan. However, in patients with delirium, neopterin levels seemed to 
be lower and tryptophan levels seemed to be higher in patients who used acetylsalicylic 
acid compared to those who did not.
The neurotransmitter acetylcholine is implicated in several processes that are impaired dur-
ing delirium, such as attention, sleep and memory, and this has led to the hypothesis that 
a cholinergic deﬁciency might be involved in the pathogenesis of delirium [34, 35]. Drugs 
with anticholinergic properties are commonly prescribed in older persons and the use of 
these drugs will result in some degree of cholinergic deﬁciency, therefore anticholinergic 
drug use might be a risk factor for delirium.
Currently, there is no consensus on the deﬁnition of anticholinergic drugs and this has 
led to the development of several ranked anticholinergic drug scales. Previous studies 
generally used one anticholinergic drug scale to assess anticholinergic drug exposure and 
additionally, used them in different ways. The available scales differ, however, substantially 
from each other in number and ranking of drugs. Unfortunately, little is known about how 
these differences in measurement affect their predictive validity with respect to clinically 
relevant outcomes, such as delirium [36].
In the study presented in chapter 3.2, three anticholinergic drug scales were used within 
the same population to investigate whether anticholinergic drug exposure on admission 
is associated with delirium on admission, length of hospital stay, postdischarge institu-
tionalization and in-hospital mortality. We demonstrated that the scale used to identify 
anticholinergic drugs signiﬁcantly affected the results. Only anticholinergic drug exposure 
measured with the Anticholinergic Risk Scale (ARS), was associated with an increased 
prevalence of delirium on admission and postdischarge institutionalization in acutely ill 
hospitalized patients. The ARS is a quick measure of anticholinergic drug burden, easy to 
apply in clinical practice, and might be a useful tool to identify patients at increased risk for 
delirium. Future research is needed to investigate whether medication reviews using the 
ARS will lead to better clinical outcomes in older patients.
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CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS
Delirium in older hospitalized patients is a major problem associated with poor clinical 
outcomes. Up-to-date, the high need to improve the prediction, detection and treatment 
of delirium is increasingly being recognized, while the underlying pathophysiology remains 
largely understudied. Adequate knowledge of the pathophysiology is required to ﬁnd 
markers for early recognition and to improve delirium prediction, prevention and treat-
ment.
Identiﬁcation of accurate biomarkers for delirium will help unraveling the complex patho-
physiology. In this thesis, several markers of different pathways were investigated and were 
found to be increased or decreased in older, acutely ill patients with delirium. The ﬁndings 
suggest that an inadequate response of the immune system, oxidative stress, loss of brain 
reserve and a disturbance in the serotonergic neurotransmission may be all involved in 
the pathophysiology of delirium in acutely ill older patients. These speculations need to 
be conﬁrmed and larger studies are needed to investigate the clinical signiﬁcance of the 
investigated markers as potential biomarkers for delirium diagnosis.
Several markers have been found to be increased or decreased in patients with delirium 
and have the potential to be a biomarker, but many of the investigated markers require 
time-consuming and expensive measurements and trained personnel which make their 
use for research purposes and clinical practice less attractive. A potential diagnostic (or 
predictive) biomarker for delirium requires a fast, simple and widely available method of 
determination. A time-consuming measurement is not preferred, given the fact that a 
person’s prognosis becomes poorer with each day that delirium persists.
The neutrophil-lymphocyte ratio, which is directly derived from the differential white blood 
cell count, is an easily applicable marker of inﬂammation and oxidative stress. Higher NLR 
levels were found in patients with delirium when compared to patients without delirium. 
If these ﬁndings are conﬁrmed in larger studies, NLR offers new opportunities for delirium 
research. It would be interesting to evaluate the discriminative power of NLR in diagnosing 
and predicting delirium in different populations and to investigate if NLR levels can predict 
poor outcomes in patients with delirium.
In this thesis, we have described differences in biochemical proﬁle between medical and 
surgical patients with delirium. These ﬁndings suggest that the markers and pathways that 
might be involved in the pathophysiology of delirium may differ between groups of patients 
with delirium and highlight the importance to perform studies in different populations. It 
might be possible that delirium care needs different approaches in different settings. A 
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major step forward in delirium research would be a large study, including several health 
care settings (e.g. surgical, medical and intensive care units), in which potential biomarkers 
and other factors are compared across different groups of patients with delirium.
Based on our ﬁndings it can be concluded that the ARS might be a suitable instrument to 
identify patients at increased risk of delirium and postdischarge institutionalization. Previ-
ous studies have shown that medication reviews can be effective in reducing anticholinergic 
drug exposure in persons aged 65 years and older [37, 38]. Moreover, it has been shown 
that in frail, acutely ill, older patients admitted to a geriatric hospital ward, anticholinergic 
drug exposure can be reduced further simply by alerting the clinician of a person’s ARS 
score and by asking the clinician to reconsider anticholinergic drug use in patients with an 
ARS score greater than 0 [38]. Therefore, it would be interesting to investigate whether 
regular medication reviews with the ARS as additional tool in every person aged 65 years 
and older performed in both the community and hospital setting will reduce delirium on 
admission and may preserve independent functioning in older persons.
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SUMMARY
Delirium – an acute neuropsychiatric syndrome – affects approximately 1 out of 3 older 
patients admitted to the hospital and is associated with poor outcomes, including pro-
longed hospital stay and increased rates of postdischarge institutionalization, cognitive 
decline and mortality. Despite the high frequency and clinical impact, this syndrome is still 
poorly understood. The aims of this thesis were to investigate the association of several 
biochemical markers and pharmacological agents with delirium in two groups of acutely 
ill hospitalized patients aged 65 years and older. The ﬁndings may contribute to a better 
understanding of the pathophysiology and may help to ﬁnd markers for early recognition 
and to improve delirium prevention, prediction and treatment.
Chapter 1 gives a general introduction to the research topics of this thesis. Chapter 2 
focuses on several mechanisms that might play a role in the pathophysiology of delirium. In 
chapter 2.1 the association of plasma levels of neopterin, interleukin-6 (IL-6) and insulin-
like growth factor-1 (IGF-1) with delirium was investigated. Patients with delirium had sta-
tistically signiﬁcantly higher levels of neopterin and IL-6 as well as statistically signiﬁcantly 
lower levels of IGF-1 than patients without delirium. These ﬁndings suggest that activation 
of the immune system, oxidative stress and an increased vulnerability of the brain (due to 
decreased neuroprotection) might be involved in the pathogenesis of delirium.
Chapter 2.2 focuses on disturbances in serotonergic and dopaminergic neurotransmission 
as well as oxidative stress in delirium. For this purpose, levels of amino acids, amino acid 
ratios and dopamine’s metabolite homovanillic acid (HVA) were investigated. Patients with 
delirium had higher phenylalanine/tyrosine ratios, lower ratios of tryptophan to the other 
large neutral amino acids (LNAAs) and lower levels of arginine and citrulline than patients 
without delirium. These ﬁndings suggest that a decreased availability of tetrahydrobi-
opterin, disturbed serotonergic neurotransmission and an increased status of oxidative 
stress may play a role in the pathogenesis of delirium. No differences in phenylalanine/
LNAAs ratios, tyrosine/LNAAs ratios and HVA levels were found between patients with 
and without delirium, suggesting that the dopaminergic neurotransmission is not impaired 
during delirium.
In chapter 2.3, the association of the neutrophil-lymphocyte ratio (NLR) and other, more 
conventional, inﬂammatory markers (i.e. white blood cell (WBC) count, neutrophils, 
lymphocytes and C-reactive protein (CRP)) with delirium was investigated. Patients with 
delirium had increased NLR levels, even after adjustment for inﬂammatory markers and 
additionally, no differences were found in the levels of CRP, WBC, neutrophils and lympho-
cytes. These ﬁndings might suggest an independent role of NLR in delirium above conven-
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tional inﬂammatory markers and support the hypothesis that an inadequate response of 
the immune system and oxidative stress may play a role in the pathogenesis of delirium.
Chapter 2.4 focuses on potential differences in blood-based markers among different cat-
egories of patients with delirium. In this chapter, mean plasma levels of neopterin, amino 
acids, amino acid ratios and HVA in acutely ill medical patients with delirium and patients 
with delirium after elective cardiac surgery were compared. Higher neopterin levels and 
higher phenylalanine/tyrosine ratios were found in acutely ill medical patients with delirium 
than in patients with delirium after elective cardiac surgery. Furthermore, substantial dif-
ferences in determinants of neopterin levels were found between the two populations. 
C-reactive protein levels were the strongest determinant of neopterin levels in acutely 
ill medical patients with delirium, whereas the estimated glomerular ﬁltration rate was 
the strongest determinant of neopterin in elective cardiosurgical patients with delirium. 
Thus, in acutely ill medical patients, neopterin levels are probably mainly determined by 
inﬂammation/oxidative stress, whereas in elective cardiosurgical patients, neopterin levels 
are mainly driven by renal function/ﬂuid status. These ﬁndings suggest that delirium might 
have different pathophysiological mechanisms depending on the population studied.
Chapter 3 focuses on the role of pharmacological agents in delirium. In chapter 3.1, the 
possible inﬂuence of the use of acetylsalicylic acid on neopterin and tryptophan levels in 
patients with and without delirium was investigated. No differences were found in mean 
levels of neopterin and tryptophan between users and non-users. However, in patients 
with delirium, neopterin levels seemed to be lower and tryptophan levels seemed to be 
higher in patients who used acetylsalicylic acid compared to those who did not.
In chapter 3.2, the possible association between anticholinergic drug use and delirium 
on admission, length of hospital stay, postdischarge institutionalization and in-hospital 
mortality was investigated. Anticholinergic drug exposure on admission was quantiﬁed 
with three anticholinergic drug scales, i.e. the Anticholinergic Risk Scale (ARS), the Anti-
cholinergic Cognitive Burden scale (ACB) and the list of Chew et al. (Chew). Substantial 
differences were found in the estimation of anticholinergic drug exposure among the ARS, 
ACB and Chew as well as in the presence of associations with clinically relevant outcomes. 
Only anticholinergic drug exposure measured with the ARS was associated with delirium 
on admission and postdischarge institutionalization. Considering the fact that delirium and 
postdischarge institutionalization are both associated with a very poor prognosis, future 
studies are needed to investigate the clinical utility of the ARS in reducing complications 
in older persons.
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In the general discussion, chapter 4, the main ﬁndings of this thesis are discussed and 
suggestions for further research are presented. The results indicate that an inadequate 
response of the immune system, oxidative stress, loss of brain reserve and a disturbance in 
the serotonergic neurotransmission may be all involved in the pathophysiology of delirium 
in acutely ill older patients. Moreover, the ﬁndings suggest that the markers and pathways 
that might be involved in the pathophysiology of delirium in acutely ill medical patients 
may differ from those in elective cardiosurgical patients, which highlights the importance 
to perform delirium studies in different populations. Furthermore, we demonstrated that 
anticholinergic drug exposure measured with the ARS was associated with delirium on 
admission. The ARS is a quick and simple measure of anticholinergic drug exposure, easy 
to apply, and might be clinically useful in identifying patients at increased risk of develop-
ing delirium. Future studies are needed to investigate whether regular medication reviews 
using the ARS are a useful tool in order to reduce delirium in older persons.
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SAMENVATTING
Een delirium is een acute vorm van verwardheid die voorkomt bij ongeveer 1 op de 3 
ouderen die zijn opgenomen in het ziekenhuis. Een delirium is een ernstig neuropsychia-
trisch syndroom dat vaak gepaard gaat met een langer verblijf in het ziekenhuis, een 
vermindering van zelfredzaamheid, een grotere kans op het ontwikkelen van dementie 
en een verhoogd 1-jaars mortaliteitsrisico. Hoewel delirium zeer frequent voorkomt bij 
ouderen en een grote impact heeft op zowel patiënten als de gezondheidszorg, is er nog 
veel onbekend over de pathofysiologie en de mogelijke rol van geneesmiddelen bij het 
uitlokken van delirium.
Het doel van dit proefschrift was om verschillende factoren die een rol kunnen spelen in 
de pathofysiologie van delirium te onderzoeken en om de relatie tussen bepaalde groepen 
geneesmiddelen en delirium nader te evalueren. De onderzoeken die in dit proefschrift 
beschreven worden, berusten op twee studies die zijn uitgevoerd bij patiënten van 65 
jaar en ouder die acuut ziek waren opgenomen in het ziekenhuis. De bevindingen van 
dit proefschrift kunnen bijdragen aan een beter begrip van de pathofysiologie; helpen bij 
de zoektocht naar potentiële (bio)markers voor een vroege herkenning van het delirium 
en helpen bij het verbeteren van de preventie, predictie en behandeling van het delirium.
In hoofdstuk 1 wordt een algemene inleiding over delirium gegeven en worden de on-
derwerpen die in dit proefschrift aan bod komen, geïntroduceerd. In hoofdstuk 2 staan 
verschillende mechanismen centraal die een rol zouden kunnen spelen in de pathofysiolo-
gie van delirium. In hoofdstuk 2.1 werden plasma spiegels van neopterine, interleukine-6 
(IL-6) en insulin-like growth factor-1 (IGF-1) van patiënten met en zonder delirium vergele-
ken. In patiënten met een delirium werden statistisch signiﬁcant hogere neopterine en IL-6 
spiegels gevonden en statistisch signiﬁcant lagere IGF-1 spiegels dan in patiënten zonder 
delirium. Deze resultaten suggereren dat een geactiveerd immuunsysteem, oxidatieve stress 
en een verhoogde kwetsbaarheid van het brein (door een verminderde neuroprotectie) een 
rol kunnen spelen in de pathofysiologie van delirium.
In hoofdstuk 2.2 staan oxidatieve stress en verstoringen in de serotonerge en dopami-
nerge neurotransmissie als mogelijk onderliggende mechanismen voor delirium centraal. 
Om de eventuele betrokkenheid van deze mechanismen bij delirium te bestuderen, werden 
in het bloed van patiënten met en zonder delirium een aantal markers bepaald, namelijk 
diverse aminozuren (enkele zijn voorlopers van neurotransmitters) en homovanillinezuur 
(een metaboliet van dopamine), en werden verschillende ratio’s van aminozuren berekend. 
Patiënten met een delirium hadden statistisch signiﬁcant hogere fenylalanine/tyrosine 
ratio’s, lagere ratio’s van tryptofaan ten opzichte van de andere grote neutrale aminozuren 
en lagere arginine en citrulline spiegels dan patiënten zonder delirium. Deze resultaten 
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suggereren dat een verminderde beschikbaarheid aan tetrahydrobiopterine (een essen-
tiële cofactor bij de vorming van serotonine en dopamine), een verstoorde serotonerge 
neurotransmissie en een verhoogde staat van oxidatieve stress een rol kunnen spelen in 
de pathofysiologie van delirium. Er werden geen verschillen gevonden in de dopaminerge 
markers in patiënten met en zonder delirium.
In de pilotstudie die beschreven wordt in hoofdstuk 2.3 werden in patiënten met en zonder 
delirium diverse inﬂammatoire markers onderzocht die routinematig bepaald kunnen worden, 
namelijk de neutroﬁelen-lymfocyten ratio (NLR) en de meer traditionele inﬂammatoire mar-
kers, zoals C-reactive protein (CRP), het totale aantal leukocyten, neutroﬁelen en lymfocyten. 
Patiënten met een delirium hadden statistisch signiﬁcant hogere NLR waarden dan patiënten 
zonder delirium, zelfs na correctie voor de andere inﬂammatoire markers. Er werden geen 
verschillen gevonden in CRP spiegels en het totale aantal leukocyten, neutroﬁelen en lymfo-
cyten. Deze resultaten suggereren dat de NLR mogelijk een onafhankelijke en tevens sterkere 
rol speelt in delirium dan de traditionele inﬂammatoire markers. Daarnaast ondersteunen de 
resultaten de hypothese dat een verstoorde reactie van het immuunsysteem en oxidatieve 
stress een rol kunnen spelen in de pathofysiologie van delirium.
In toenemende mate wordt er gesuggereerd dat er mogelijk verschillen bestaan in 
biologische markers tussen verschillende groepen patiënten met een delirium. Om te 
onderzoeken of er verschillen bestaan, werden in hoofdstuk 2.4 plasma spiegels van 
neopterine, homovanillinezuur, aminozuren en aminozuurratio’s van acuut zieke patiënten 
met een delirium, die opgenomen waren bij de afdeling geriatrie, vergeleken met die van 
patiënten met een delirium na een electieve hartoperatie. In acuut zieke patiënten met een 
delirium werden statistisch signiﬁcant hogere neopterine spiegels en hogere fenylalanine/
tyrosine ratio’s gevonden dan in patiënten met een delirium na een electieve hartoperatie. 
Daarnaast werden er grote verschillen gevonden in factoren die de neopterine spiegel 
bepaalden. In acuut zieke patiënten met een delirium was CRP de sterkste determinant 
van de neopterine spiegel, terwijl de geschatte glomerulaire ﬁltratiesnelheid de sterkste 
determinant van de neopterine spiegel was in patiënten met een delirium na een electieve 
hartoperatie. Deze bevindingen suggereren dat neopterine in acuut zieke patiënten met 
een delirium voornamelijk bepaald wordt door een onderliggende ontstekingsreactie of 
oxidatieve stress, terwijl in patiënten met een delirium na een electieve hartoperatie, neop-
terine waarschijnlijk voornamelijk bepaald wordt door de nierfunctie of de vullingsstatus 
van de patiënt. Deze resultaten suggereren dat de pathofysiologie van delirium mogelijk 
verschilt tussen groepen patiënten met een delirium.
In hoofdstuk 3 staat de mogelijke relatie tussen geneesmiddelen en delirium centraal. 
In hoofdstuk 3.1 werd de mogelijke invloed van het gebruik van acetylsalicylzuur op 
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neopterine en tryptofaan onderzocht bij patiënten met en zonder delirium. Er werden 
geen verschillen gevonden in neopterine en tryptofaan spiegels tussen patiënten die 
wel en geen acetylsalicylzuur gebruikten. Wel leken bij patiënten met een delirium de 
neopterine spiegels lager en de tryptofaan spiegels hoger bij mensen die acetylsalicylzuur 
gebruikten dan bij patiënten die dit middel niet gebruikten, maar dit verschil was niet 
statistisch signiﬁcant.
In hoofdstuk 3.2 werd het mogelijke verband tussen het gebruik van anticholinerge me-
dicatie en delirium bij opname, opnameduur, institutionalisering na ontslag en overlijden 
in het ziekenhuis, onderzocht. Het gebruik van anticholinerge medicatie bij opname werd 
vastgesteld met drie anticholinerge scoringslijsten, namelijk de Anticholinergic Risk Scale 
(ARS), de Anticholinergic Cognitive Burden Scale (ACB) en de lijst van Chew et al. (Chew). 
Er werden grote verschillen gevonden in de mate van blootstelling aan anticholinerge 
medicatie wanneer gebruik werd gemaakt van de drie verschillende lijsten. Daarnaast 
werden met de ARS, de ACB en de Chew niet dezelfde associaties met de onderzochte uit-
komstmaten gevonden. Patiënten die volgens de ARS anticholinerge medicatie gebruikten, 
hadden een verhoogde kans op een delirium bij opname en een verhoogde kans om ont-
slagen te worden naar een instelling. Aangezien zowel een delirium als institutionalisering 
geassocieerd zijn met een slechte prognose, zijn vervolgstudies nodig om te onderzoeken 
of de ARS een bruikbaar hulpmiddel is om bij ouderen de kans op negatieve uitkomsten 
te verminderen.
In hoofdstuk 4 worden de belangrijkste bevindingen van dit proefschrift bediscussieerd en 
worden suggesties voor vervolgonderzoek gepresenteerd. De resultaten van dit proefschrift 
laten zien dat een inadequate reactie van het immuunsysteem, oxidatieve stress, een ver-
hoogde kwetsbaarheid van het brein en een verstoring in de serotonerge neurotransmissie 
waarschijnlijk allemaal een rol spelen in de pathofysiologie van delirium bij acuut zieke 
oudere patiënten. Daarnaast suggereren de resultaten dat bij acuut zieke ouderen mogelijk 
andere markers en mechanismen een rol spelen in de pathofysiologie van delirium dan bij 
ouderen die een electieve hartoperatie hebben ondergaan. Deze bevinding onderstreept 
het belang om bij verschillende populaties onderzoek te doen naar delirium. Verder heb-
ben we laten zien dat ouderen die volgens de ARS anticholinerge medicatie gebruiken 
een verhoogde kans hebben op een delirium bij opname in het ziekenhuis. Met de ARS 
kan makkelijk en snel worden vastgesteld of iemand anticholinerge medicatie gebruikt en 
dus is de ARS mogelijk een bruikbaar hulpmiddel om patiënten te identiﬁceren die een 
verhoogd risico hebben op het ontwikkelen van een delirium. Vervolgstudies zijn nodig om 
te onderzoeken of medicatiereviews waarbij aanvullend wordt gecontroleerd op medicatie 
van de ARS lijst, kunnen helpen bij het terugdringen van delirium bij ouderen.
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DANKWOORD
Dit dankwoord is dan wel één van de laatste hoofdstukken van mijn proefschrift, maar is 
daarom zeker niet minder belangrijk. Ik weet niet of het ooit onderzocht is, maar ik gok 
dat het dankwoord het meest gelezen hoofdstuk van een proefschrift is. Eigenlijk is dat 
ook wel te begrijpen, want promoveren doe je niet alleen. Via dit dankwoord wil ik dan 
ook iedereen bedanken die heeft bijgedragen aan de totstandkoming van dit proefschrift. 
Een aantal mensen wil ik graag in het bijzonder bedanken, want zonder hun hulp, kennis, 
suggesties, waardevolle feedback en luisterende oren was dit promotietraject toch wel een 
zware opgave geworden.
Allereerst wil ik mijn copromotor en tevens supervisor van mijn masteronderzoek be-
danken, Francesco Mattace-Raso. Beste Francesco, op 5 juli 2012 rond kwart over drie 
hebben wij elkaar voor het eerst ontmoet. Op dat moment wisten wij geen van beiden dat 
deze dag een zeer uitdagende wending aan onze levens zou gaan geven. Ik zal deze dag 
in ieder geval nooit vergeten! Ik had vlak voor onze ontmoeting te horen gekregen dat 
het onderzoeksproject van mijn eerste keus al vergeven was en toen vertelde jij mij héél 
enthousiast dat je nog wel een delirium-project had. Ik deelde jouw enthousiasme totaal 
niet, want ik had van te voren besloten dat ik geen onderzoek wilde doen dat ook maar 
IETS met hersenen te maken had. Gelukkig is nee bij mij niet altijd nee en besloot ik om 
mij gedurende 6 maanden met dit project bezig te houden. Een keus met verstrekkende 
gevolgen, want op 6 mei 2013, toen ik mijn verslag kwam bespreken, liet je al vrij snel 
de vraag vallen of ik geen promotieonderzoek wilde doen. Ik had geen idee waar ik aan 
begon en jij volgens mij ook niet (Weet je het zeker, Angelique? Weet je het echt zeker? 
Moet je niet eerst een promotie bijwonen?), maar ik bleef dit keer bij mijn besluit, waar jij 
en ik nog steeds heel blij mee zijn! Natuurlijk was het tijdens het promotietraject niet altijd 
rozengeur en maneschijn. Jouw Italiaanse temperament en mijn Rotterdamse directheid 
konden soms ﬂink botsen en er zijn genoeg momenten geweest waarop ik je graag achter 
het behang had geplakt (wederzijds -), maar zonder jou was het mij waarschijnlijk nooit 
gelukt om dit traject te doorlopen. Je stond én staat altijd voor me klaar, verkeerde soms 
in meer spanning dan ik wanneer we op een reactie van een tijdschrift zaten te wachten 
en gelukkig schreeuwde je het nog net niet van de daken hoe blij en trots je was als we 
weer iets moois hadden bereikt. En terwijl ik dit allemaal schrijf, hoor ik je zeggen ‘less is 
more’, dus ik ga afronden.
Francesco, ik heb je in de afgelopen jaren veel te weinig bedankt en ik vind dit een mooie 
plek om mijn waardering nu maar eens voor eeuwig vast te leggen: Francesco, bedankt 
voor alles! En ik hoop dat we in de toekomst nog veel wetenschappelijke missies zullen 
delen.
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Veel dank gaat ook uit naar mijn promotor, professor Van Saase. Beste Jan, je bent hal-
verwege het traject in de rijdende trein gestapt die op 7 maart hopelijk zijn eindbestem-
ming gaat bereiken. Onze directe samenwerking is dan misschien van beperkte omvang 
geweest, maar telkens bleek maar weer dat je altijd goed op de hoogte was van wat er 
reilde en zeilde. Via deze weg wil ik je graag bedanken voor jouw ondersteunende en 
relativerende inbreng tijdens mijn promotietraject. Als geen ander wist je altijd op humo-
ristische wijze duidelijk te maken dat de weersomstandigheden in onderzoeksland heel erg 
op het Nederlandse klimaat lijken, namelijk totaal onvoorspelbaar!
Verder wil ik ook graag mijn tweede supervisor van mijn masteronderzoek bedanken, Durk 
Fekkes. Beste Durk, heel erg bedankt dat je mij tijdens het onderzoek de gelegenheid hebt 
geboden om mijn vaardigheden in het lab uit te breiden en voor jouw vertrouwen in mijn 
analysecapaciteiten. Ik heb heel veel van jou geleerd, vooral op biochemisch vlak. Jouw 
kennis van de diverse biomarkers is van onschatbare waarde geweest!
Ook Ans Voskuilen-Kooijman kan ik op deze plaats niet vergeten te noemen. Beste Ans, 
ik vond het ﬁjn om met je samen te werken in het lab. Ik heb veel van je geleerd en ik 
wil je bij deze hartelijk danken voor jouw begeleiding en ondersteuning bij de diverse 
labbepalingen!
Graag wil ik de leden van de promotiecommissie bedanken. Beste professor Van Gelder, 
professor Blauw en professor Van Swieten, hartelijk dank voor het lezen en beoordelen van 
mijn proefschrift. Beste professor Van der Cammen, professor Stricker, professor Hoogen-
dijk en professor Van Schaik, hartelijk dank voor jullie bereidheid om plaats te nemen in 
de grote commissie.
Nicole, ondanks dat je niet betrokken bent geweest bij mijn promotieonderzoek, wil ik je 
toch enorm bedanken. Jij bent in 2012 het startpunt geweest van dit geweldige traject. 
Natuurlijk vond ik het jammer dat ik als farmaciestudent geen masteronderzoek kon 
verrichten binnen de IMPROveFALL studie, maar gelukkig bracht je mij in contact met 
Francesco. Mede dankzij jou ben ik in dit mooie promotietraject gerold.
Alle co-auteurs, hartelijk dank voor jullie kritische en waardevolle feedback op de diverse 
manuscripten.
Verder wil ik graag alle artsen en verpleegkundigen bedanken van alle deelnemende 
afdelingen in het Erasmus MC en Havenziekenhuis die hebben geholpen bij het ten uit-
voer brengen van de DITO studie. Hartelijk dank voor jullie hulp bij het screenen op en 
diagnosticeren van delirium! Extra veel dank gaat uit naar Lakshmi, Gea en de andere 
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assistenten/verpleegkundigen die bloed hebben afgenomen voor de studie. Jullie inzet 
was onmisbaar!
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